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Centrosomes are the major microtubule-organizing centers of the cell, and play a key role in 
organizing the bipolar mitotic spindle. Precise regulation of centrosome number is therefore 
critical for accurate chromosome segregation and the maintenance of genomic integrity. The 
consequences of centrosome loss, however, have been difficult to study due to a lack of 
specific tools that allow persistent and reversible centrosome depletion. In the first chapter of 
this thesis, we combined gene targeting with an auxin-inducible degradation system to 
achieve rapid, titratable, and reversible control of Polo-like kinase 4 (Plk4), a master 
regulator of centrosome biogenesis. Depletion of Plk4 led to a failure of centrosome 
duplication that, unexpectedly, produced an irreversible cell cycle arrest within a few 
divisions. This arrest was not a result of a prolonged mitosis, chromosome segregation errors 
or cytokinesis failure. Depleting p53 allowed cells that failed centrosome duplication to 
proliferate indefinitely, indicating the presence of a p53-dependent surveillance mechanism 
that protects against genome instability by preventing cell growth following centrosome 
duplication failure. However, the mechanism by which p53 is activated in response to 
centrosome loss was unknown. 
 In the second chapter, we describe how we performed a genome-wide CRISPR/Cas9 
knockout screens to identify a USP28-53BP1-p53-p21 signaling axis at the core of the 
centrosome surveillance pathway. We show that USP28 and 53BP1 act to stabilize p53 
following centrosome loss and demonstrate this function to be independent of their 
previously characterized role in the DNA damage response. Surprisingly, the USP28-53BP1-
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p53-p21 signaling pathway is also required to arrest cell growth following a prolonged 
prometaphase. We therefore propose that centrosome loss or a prolonged mitosis activate a 
common signaling pathway that acts to prevent the growth of cells with an increased 
propensity for mitotic errors. 
 Notably, most cancer cells have a disrupted p53 or p21 pathway, which allows them 
to proliferate indefinitely in the absence of centrosomes. In the last chapter of this thesis, we 
illustrate an exception to this trend, identifying a subset of breast cancers that exhibit 
profound sensitivity to centrosome loss that is independent of the mitotic surveillance 
pathway. We find this sensitivity to be dependent on the overexpression of TRIM37, an E3 
ubiquitin ligase encoded within the 17q23 amplicon found in this subset of breast cancers. 
Timelapse studies show that centrosome depletion in these cells leads to dramatically 
prolonged mitoses that largely end in mitotic slippage. Subsequent analyses show that 
pericentriolar material (PCM) is depleted when TRIM37 is overexpressed, and that this 
suppresses the ability of these cells to organize a bipolar mitotic spindle through 
compensating, non-centrosomal pathways. Together, these results reveal a synthetic lethal 
vulnerability in breast cancers harboring the 17q23 amplicon that could be exploited 
therapeutically. In summary, this thesis describes the development of precise tools with 
which to study centrosome depletion, and reports the cellular consequences of centrosome 
loss in distinct cellular contexts.   
 
 Primary Reader: Andrew Holland, Ph.D. 





I would first and foremost like to acknowledge my thesis advisor, Dr. Andrew Holland. It has 
been an incredible delight and privilege to join the lab at its inception and work so closely 
with Andrew. His intellectual energy and enthusiasm has been a regular source of inspiration 
– whether exercised while poring over data together, or during philosophical discussions 
about the state of science and society, his shared insights and curiosity have continually 
motivated me and enhanced the caliber of my critical thinking. Of course, his mentorship 
also extends beyond knowledge transmission: Andrew has actively sought to provide a 
wealth of opportunities to collaborate, establish new techniques in the lab, apply for honors, 
and present our work in various settings. These opportunities cost him considerable time and 
money, but afforded me the broad experiences that enabled me to blossom as a scientist. 
Altogether, I am deeply grateful to Andrew’s thoughtful and generous approach to helping 
me reach my full potential in his lab. 
 Coming in to work every day was a joy, and this is due in large part to sharing the 
space with spectacular lab mates. Michelle Levine, in particular, was my bay mate from day 
one, and has been an incredible role model for humor, positivity, social grace, and generosity 
over the past five years. I could not have imagined a better partner with whom to go through 
the trials and triumphs of graduate school. Over the years, we were fortunate to attract a large 
cohort of wonderful lab mates, each of which has such unique and delightful strengths. To 
highlight a few, the formidable Thao Phan, who survived my rotation mentorship to blossom 
in the lab and become a trusted confidant. I cherish our late-night, contemplative 
 v 
conversations, and hope there will be many more to come. To Lauren Evans, who is a 
bottomless well of positivity and can always put a positive spin on something when I need it 
the most. And to Phillip Scott, who has nourished me with countless snacks and, more 
importantly, his uniquely comedic take on the world. 
 Beyond the lab, I have been fortunate to have made such wonderful friends through 
my graduate program. We have shared so many adventures around the city, laughing together 
when times are good, and supporting one another when they aren’t. Some of my fondest grad 
school memories are of commiseration with these friends after tough times in lab, during 
which they inevitably help me see the funny side of it all. Cheers especially to Karole 
D’Orazio and Joyce Lee, who I have always admired for their work-life balance and 
unfailing sense of humor even in seemingly dire times. 
 None of this would be possible without the dedication of the BCMB administration, 
who brought all of us together. It is thanks to the hard work of Arhonda Gogos and Sharon 
Root in the office, and Carolyn Machamer for spearheading the program for so many years, 
that this program continues to run smoothly and attract the wonderful people that it does. 
 I would also like to thank my thesis committee, Dr. Randy Reed, Dr. Geraldine 
Seydoux, and Dr. Seth Margolis, for their support over the years, and for valuable 
perspectives that helped us focus on the larger picture. Special thanks to Seth for his 
readiness to wax philosophical, leading to many fun and enriching discussions on finding 
meaning in science and career. 
 Lastly, I would like to thank my earliest scientific mentors: my parents, who are 
themselves academics. They cultivated my curiosity about the micro- and macroscopic world 
from as early as I can remember! I can recall many inquisitive discussions at the dinner table, 
 vi 
during which they would gently probe my understanding of topics spanning from electron 
behavior to planetary orbits, and everything in between. These countless, casually scientific 
conversations taught me to wonder about the “why” and the “how” underlying anything I 
observed. Furthermore, they encouraged me to pursue my interests, and were tireless 
cheerleaders as I progressed in my schooling and research path. They provided love, support, 
and humor through good times and bad, and on top of that, demonstrate a lifestyle of constant 
learning, adventure, and giving that I aspire to. Knowing that I am simply the product of a 
fortunate series of incredibly generous mentors, I can scarcely comprehend how lucky I am 





Table of Contents 
Acknowledgements ................................................................................................................ iv	  
List of Figures ......................................................................................................................... ix	  
Introduction ............................................................................................................................. 1	  
1.1   Overview ..................................................................................................................... 1	  
1.1.1   Centrosome introduction .................................................................................... 1	  
1.1.2   Centrosome duplication ..................................................................................... 2	  
1.1.3   Plk4: the centrosome master regulator ............................................................... 3	  
Developing a tool to study centriole biology ......................................................................... 4	  
2.1   Overview ..................................................................................................................... 4	  
2.1.1   Current limitations in tools to study centriole biology ...................................... 4	  
2.2   A novel system for rapidly and reversibly controlling Plk4 levels ............................. 5	  
2.3   A graded reduction in protein levels reveals a threshold level of Plk4 required for 
centriole duplication ............................................................................................................ 7	  
2.4   The centriole localization of STIL is uniquely sensitive to the levels of Plk4 ........... 8	  
2.5   Cells lacking Plk4 undergo a cell cycle arrest ............................................................ 9	  
2.6   The cell cycle arrest following centriole duplication failure is not caused by a 
prolonged mitosis. ............................................................................................................. 10	  
2.7   Repression of p53 allows Plk4-depleted cells to proliferate and become acentriolar
........................................................................................................................................... 12	  
2.8   Restoration of endogenous Plk4 levels in acentriolar cells results in de novo 
centriole formation. ........................................................................................................... 14	  
2.9   Discussion ................................................................................................................. 17	  
2.10   Figures and Legends ............................................................................................... 22	  
Identification of a mitotic surveillance pathway ................................................................ 45	  
3.1   Introduction ............................................................................................................... 45	  
3.2   A chemical genetic system to activate the centrosome surveillance pathway .......... 46	  
3.3   Genome-scale CRISPR/Cas9 knockout screen to identify components of the 
centrosome surveillance pathway ..................................................................................... 47	  
3.3.1   53BP1 is required to stabilize p53 following centrosome loss ........................ 48	  
3.3.2   USP28 functions together with 53BP1 to stabilize p53 following centrosome 
loss .............................................................................................................................. 49	  
 viii 
3.3.3   p21 acts downstream of p53 in the centrosome surveillance pathway ............ 50	  
3.3.4   The centrosome surveillance pathway is not activated by DNA damage ........ 51	  
3.4   The cell cycle arrest induced by prolonged prometaphase requires the same 
signaling components as the centrosome surveillance pathway ....................................... 53	  
3.5   Distinct signal transduction cascades activate p53 in response to centrosome 
amplification or centrosome loss ...................................................................................... 55	  
3.6   Discussion ................................................................................................................. 55	  
3.7   Figures and Legends ................................................................................................. 57	  
Centrosome loss is synthetic lethal with high TRIM37 expression in 17q23-amplified 
breast cancer cells ................................................................................................................. 73	  
4.1   Introduction ............................................................................................................... 73	  
4.2   MCF-7 breast cancer cells are hypersensitive to centrinone, independent of the 
mitotic surveillance pathway ............................................................................................ 75	  
4.3   The sensitivity of MCF-7 cells to centrinone is dependent on overexpression of the 
TRIM37 oncoprotein ........................................................................................................ 76	  
4.4   TRIM37 overexpression is synthetic lethal with PLK4 inhibition in HCT116 and 
RPE-1 cells ........................................................................................................................ 77	  
4.5   PLK4 inhibition is synthetic lethal in 17q23 amplified breast cancer cells .............. 78	  
4.6   MCF-7s undergo prolonged and aberrant mitosis upon centrinone treatment ......... 78	  
4.7   Identifying TRIM37 proximity partners using mTurbo biotin labeling ................... 79	  
4.8   Overexpression of TRIM37 reduces PCM levels and suppresses microtubule 
nucleation in MCF-7 cells ................................................................................................. 80	  
4.9   Non-centrosomal PCM aids in mitotic spindle assembly when centrosomes are 
depleted ............................................................................................................................. 81	  
4.10   TRIM37 levels are cell cycle regulated .................................................................. 82	  
4.11   TRIM37 overexpression drives genomic instability ............................................... 83	  
4.13   Discussion ............................................................................................................... 84	  
4.14   Figures and Legends ............................................................................................... 86	  
Materials and Methods ....................................................................................................... 105	  
References ............................................................................................................................ 120	  





List of Figures 
Figure 1. Generation of Plk4AID/AID cells. ............................................................................... 22	  
Figure 2. Inducible destruction of endogenous Plk4. ............................................................. 24	  
Figure 3. The centriole localization of STIL requires Plk4. ................................................... 26	  
Figure 4. Destruction of Plk4 leads to a long-term growth arrest. .......................................... 27	  
Figure 5. Plk4 depletion leads to a failure of centriole duplication followed by a cell-cycle 
arrest. ............................................................................................................................... 28	  
Figure 6. The IAA-induced cell-cycle arrest is not caused by a prolonged mitosis. .............. 30	  
Figure 7. Inhibiting the activity of p38 MAPK does not prevent the cell cycle arrest caused 
by centriole duplication failure. ...................................................................................... 32	  
Figure 8. Cell cycle progression and spindle assembly in the absence of centrioles. ............. 34	  
Figure 9. Depletion of p53 allows continued growth in the absence of Plk4. ........................ 36	  
Figure 10. Restoration of Plk4 levels in acentriolar cells leads to de novo centriole formation.
 ......................................................................................................................................... 38	  
Figure 11. De novo centriole formation requires cell cycle progression. ............................... 40	  
Figure 12. De novo formed centrioles have a normal structure. ............................................. 42	  
Figure 13. De novo centrioles recruit PCM and act as MTOCs. ............................................ 43	  
Figure 14. Inhibition of analog-sensitive Plk4 leads to centrosome loss and growth arrest. .. 57	  
Figure 15. Inhibition of Plk4 kinase activity activates the centrosome surveillance pathway 
and prevents cell growth. ................................................................................................ 59	  
Figure 16. A genome-wide CRISPR/Cas9 screen identifies 53BP1 and p53 as components of 
the centrosome surveillance pathway. ............................................................................ 61	  
Figure 17. p21 and USP28 are required for the centrosome surveillance pathway. ............... 63	  
Figure 18. USP28-/- and 53BP1-/- cells activate p53 in response to DNA damage, but not 
following centrosome loss. ............................................................................................. 65	  
Figure 19. The DNA damage response and centrosome surveillance pathway are genetically 
separable. ........................................................................................................................ 67	  
Figure 20. Knockout of 53BP1 or USP28 does not allow growth in cells overexpressing Plk4.
 ......................................................................................................................................... 69	  
Figure 21. Prolonged prometaphase and centrosome loss signal through the same components 
to arrest the cell cycle. .................................................................................................... 71	  
Figure 22. PLK4 inhibition is synthetic lethal with TRIM37 amplification in 17q23-amplified 
breast cancer cells. .......................................................................................................... 86	  
 x 
Figure 23. TRIM37 overexpression in HCT116s and RPE-1s recapitulates synthetic lethality 
with centrosome loss. ...................................................................................................... 88	  
Figure 24. Additional characterization of TRIM37 expression and synthetic lethality in 17q23 
cell lines. ......................................................................................................................... 89	  
Figure 25. PLK4 inhibition triggers mitotic catastrophe in TRIM37 amplified cancer. ........ 91	  
Figure 26. mTurbo identifies putative proximity interactors of TRIM37 .............................. 93	  
Figure 27. Depleted PCM upon TRIM37-amplification is responsible for mitotic catastrophe 
in the absence of centrosomes. ........................................................................................ 95	  
Figure 28. TRIM37 suppresses microtubule organizing capacity of the centrosome. ............ 97	  
Figure 29. CEP192 is depleted following stable shRNA expression. ..................................... 97	  
Figure 30. TRIM37 protein levels are downregulated during mitosis. ................................... 99	  
Figure 31. TRIM37 overexpression results in delayed centrosome maturation during mitotic 
entry. ............................................................................................................................. 101	  







1.1   Overview 
1.1.1   Centrosome introduction 
Centrosomes are the main microtubule-organizing centers of most animal cells, and are 
comprised of a pair of centrioles surrounded by pericentriolar material (PCM) (Gonczy, 2012; 
Nigg and Raff, 2009). Centrioles act as the centrosome organizer and thus their duplication 
controls centrosome number. Like DNA, centrioles duplicate exactly once per cell cycle, with a 
single new procentriole forming on the wall of each existing centriole (Tsou and Stearns, 2006). 
This tightly controlled process ensures the generation of two centrosomes to form the poles of 
the bipolar mitotic spindle. Errors in centriole duplication lead to abnormal centrosome number, 
which can result in chromosome segregation errors and the production of aneuploid progeny 
(Ganem et al., 2009; Silkworth et al., 2009). Aberrations in centrosome number have been 
associated with several human diseases, including cancer and neurodevelopmental disorders 
(Nigg and Raff, 2009). 
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1.1.2   Centrosome duplication 
Canonical centriole duplication begins at the G1/S transition with the assembly of a single 
cartwheel structure on the wall of each pre-existing mother centriole. The cartwheel then 
templates the formation of a procentriole by providing a scaffold onto which microtubules are 
loaded (Kitagawa et al., 2011; van Breugel et al., 2011; van Breugel et al., 2014). In addition to 
this canonical pathway of centriole assembly, de novo centriole formation can occur in the 
absence of existing centrioles (Marshall et al., 2001; Miki-Noumura, 1977; Palazzo et al., 1992; 
Suh et al., 2002; Szollosi and Ozil, 1991). A striking example of this process occurs in mouse 
embryos, where cell divisions continue in the absence of centrioles until the 64-cell stage, at 
which point centrioles are created de novo (Szollosi et al., 1972). In vertebrate somatic cells, a 
variable number of de novo centrioles are generated after experimental removal of existing 
centrioles (Khodjakov et al., 2002; La Terra et al., 2005; Uetake et al., 2007). It is therefore 
thought that existing centrioles act to suppress de novo centriole assembly, although the 
molecular mechanism for this suppression remains unclear. 
 
Previous approaches to study the immediate consequence of centriole loss in human cells have 
relied on laser ablation or microsurgery (Khodjakov et al., 2002; La Terra et al., 2005; Uetake et 
al., 2007). These elegant approaches only transiently remove centrioles from a small number of 
cells. Permanent centriole loss has been achieved through the knockout of essential centriole 
components (Bazzi and Anderson, 2014; Izquierdo et al., 2014; Sir et al., 2013). Although 
informative, these studies did not address the immediate effects of centriole duplication failure 
and were unable to temporally control formation of new centrioles. 
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1.1.3   Plk4: the centrosome master regulator 
Polo-like kinase 4 (Plk4) has emerged as a conserved, dose-dependent regulator of centriole copy 
number and offers an attractive target to reversibly modulate centriole number in populations of 
cells (Bettencourt-Dias et al., 2005; Habedanck et al., 2005). Plk4 is a self-regulating enzyme 
that phosphorylates itself to promote its own destruction (Brownlee et al., 2011; Cunha-Ferreira 
et al., 2013; Cunha-Ferreira et al., 2009; Guderian et al., 2010; Holland et al., 2010a; Klebba et 
al., 2013; Rogers et al., 2009). This auto-regulated destruction plays an important role in 
controlling the abundance of endogenous Plk4 and thereby helps to limit centriole duplication to 






Developing a tool to study centriole biology 
Modified from: Lambrus BG, Uetake Y, Clutario KM, Daggubati V, Snyder M, Sluder G, 
Holland AJ. (2015) p53 protects against genome instability following centriole duplication 
failure. Journal of Cell Biology. doi: 10.1083/jcb.201502089. 
2.1   Overview 
2.1.1   Current limitations in tools to study centriole biology 
Centriole function has been difficult to study due to a lack of specific tools that allow persistent 
and reversible centriole depletion. One attractive target that controls this process is Plk4, the 
master regulator of centriole biogenesis. RNA interference and knock-in approaches have been 
used to inhibit Plk4 function, but these strategies are slow-acting and are not readily reversible. 
Inhibition of Plk4 kinase activity offers a powerful alternative to manipulate Plk4 function. 
However, specific kinase inhibitors are difficult to develop (Holland and Cleveland, 2014; 
Mason et al., 2014). In addition, inhibiting Plk4 activity greatly increases protein abundance, 
making it challenging to dissect the relative contribution of loss of kinase activity and increased 
protein abundance (Holland et al., 2010a).  
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In this study, we developed a chemical genetics approach to rapidly and reversibly control Plk4 
protein abundance in cells. Manipulating endogenous Plk4 levels allowed the reversible 
depletion of centrioles from populations of cycling cells and uncovered the existence of a p53-
dependent pathway that guards against genome instability by preventing cellular proliferation 
following centriole duplication failure. By taking advantage of the acute and titratable depletion 
of Plk4, our data define the threshold level of Plk4 required for centriole assembly and establish 
the consequence of acute Plk4 depletion on centriole composition.  
 
2.2   A novel system for rapidly and reversibly controlling Plk4 levels  
To study the immediate effects caused by Plk4 depletion, we turned to an auxin-inducible 
degradation system that allows for post-translational control of protein abundance with the plant 
hormone auxin (Nishimura et al., 2009). In plants, auxin promotes the binding of the F-box 
protein osTIR1 to proteins containing an auxin-inducible degron (AID). In the presence of auxin, 
osTIR1 recruits AID-containing substrates to the Skp1, Cullin and F-Box (SCF) ubiquitin ligase, 
which ubiquitinates the AID-containing protein and targets it for proteasomal degradation. 
Ectopic expression of osTIR1 in mammalian cells generates an SCFTIR1 complex and enables 
auxin-inducible destruction of AID-tagged transgenes (Holland et al., 2012a), suggesting that the 
AID system could also be applied to post-translationally regulate the stability and abundance of 
endogenous Plk4.  
 
We used sequential rounds of gene targeting to knock-in the AID onto the C-terminus of both 
endogenous Plk4 alleles in non-transformed, telomerase-immortalized, human RPE-1 cells (Fig. 
1A-B). To facilitate detection, each Plk4AID allele was tagged at the C-terminus with a HA or 3x 
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FLAG tag. Two Plk4AID-HA/AID-3xFLAG (hereafter referred to as Plk4AID/AID) clones were obtained 
and behaved similarly in all assays. Plk4AID/AID cells exhibited normal centrosome copy number 
and cell cycle profiles (Fig. 1C-D), and both Plk4AID-HA and Plk4AID-FLAG localized to the 
centrioles of cells in interphase and mitosis in a manner that was indistinguishable from wild 
type Plk4 (Fig. 1E). We conclude that Plk4AID is capable of supporting Plk4 function(s) in 
centriole duplication.  
 
We stably expressed osTIR1-9xMyc in Plk4AID/AID cells to place the stability of endogenous 
Plk4AID under the control of exogenous auxin (Fig. 2A).  
To analyze Plk4 protein levels, we immunoprecipitated Plk4AID-3xFLAG from cell lysates using a 
FLAG antibody and determined the abundance of Plk4 by immunoblot. Addition of auxin (IAA) 
to Plk4AID/AID cells led to rapid Plk4 degradation, with Plk4 falling below the limit of detection 
within 10 minutes of IAA addition (Fig. 2B). The level of Plk4 at the centrosome was measured 
at various times after IAA addition using antibodies raised to the FLAG tag or to the C-terminus 
of Plk4. Staining with the monoclonal FLAG antibody revealed that the level of Plk4 at the 
centrosomes of interphase cells declined by > 95% within 30 minutes of IAA addition (Fig. 
2C,D), while staining with a polyclonal antibody to the C-terminus of Plk4 revealed a > 80% 
reduction during the same time period (Fig. 1F). Plk4 destruction occurred in all cell cycle 
phases (Fig. 2E) and required the presence of the osTIR1 F-box protein (Fig. 1G). Importantly, 
the degradation of Plk4 was fully reversible, with the level of Plk4 at the centriole recovering to 
original levels within 3 hours of IAA removal (Fig. 2F).  
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To examine whether treatment with IAA leads to the expected failure of centriole duplication, 
we assessed centriole number in cells undergoing mitosis one cell cycle (30 hours) after IAA 
addition. In untreated Plk4AID/AID cells, centriole duplication occurred successfully in > 90% of 
cells (0 µM IAA, Fig. 3A,B). By contrast, IAA addition caused a failure of centriole duplication 
in > 90% of Plk4AID/AID cells (500 µM IAA, Fig. 3A,B). We conclude that Plk4AID/AID cells offer 
a new tool to achieve rapid and reversible depletion of endogenous Plk4. 
 
2.3   A graded reduction in protein levels reveals a threshold level of Plk4 
required for centriole duplication 
Reduced expression of Plk4 has been associated with tumorigenesis, but it remains unknown 
how much Plk4 protein is required for centriole duplication (Ko et al., 2005; Liu et al., 2012; 
Pellegrino et al., 2010). Since Plk4 autoregulates its own stability, generating a progressive 
reduction in Plk4 protein levels is challenging, as a reduced abundance of Plk4 mRNA may not 
lead to a comparable downregulation of Plk4 protein (Holland et al., 2012a). We therefore set out 
to use auxin-inducible destruction to generate a graded reduction in Plk4 levels. We used 
quantitative microscopy with directly labeled Plk4 primary antibodies to determine the 
abundance of Plk4 at the centriole in cells treated with various concentrations of IAA. Exposing 
Plk4AID/AID cells to increasing concentrations of IAA resulted in gradual reduction in the average 
level of Plk4 at the centriole (Fig. 3A). We examined whether centriole duplication occurred 
successfully with different levels of Plk4 protein. In cells treated with 1 µM IAA, the average 
level of Plk4 at the centrosome was 81% of that in untreated cells (Fig. 3A,B). Under these 
conditions, centrioles duplicated in > 75% of cells. However, at 10 µM IAA, while centrosomal 
Plk4 levels were maintained at 57% of that in control cells, < 10% of cells underwent centriole 
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duplication (Fig. 3A,B). We conclude that Plk4 levels are finely balanced and that a < 2-fold 
reduction in the level of Plk4 at the centrosome leads to a failure of centriole duplication. 
 
2.4   The centriole localization of STIL is uniquely sensitive to the levels of 
Plk4 
RNAi of Plk4 leads to slow protein depletion making it challenging to distinguish between direct 
and indirect effects of Plk4 removal. The ability to rapidly remove Plk4 from cells provided an 
opportunity to identify proteins that directly depend on Plk4 for recruitment to the centriole. We 
used immunofluorescence microscopy to examine the abundance of 10 proteins (CPAP, 
CEP135, CEP152, CEP192, SAS6, CNAP1, CEP164, Centrin, γ-tubulin and STIL) at the 
centrosome 1 hour after Plk4 destruction with IAA. Since the abundance of several centriole 
proteins are reduced after mitosis (Arquint and Nigg, 2014; Arquint et al., 2012; Strnad et al., 
2007; Tang et al., 2009; Tang et al., 2011), our measurements were made in S/G2 cells that were 
marked by the presence of CENP-F (Hussein and Taylor, 2002). Of the 10 proteins examined, 
the localization of STIL was uniquely sensitive to a reduction in Plk4 levels: the abundance of 
STIL at the centriole was reduced by > 75% 1 hour after IAA addition, while total protein levels 
remained unchanged (Fig. 3C). These data are consistent with a recent study showing that Plk4 
binds to STIL (Ohta et al., 2014). STIL has been proposed to recruit SAS6 to the centriole 
though a direct, phosphorylation dependent interaction (Arquint et al., 2012; Dzhindzhev et al., 
2014; Ohta et al., 2014; Tang et al., 2011; Vulprecht et al., 2012). However, while STIL levels 
declined dramatically by one hour after acute Plk4 destruction, we observed only a modest 
change in centriole SAS6 levels, suggesting STIL is not required to maintain existing SAS6 at 
the centriole (Fig. 3C).  
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2.5   Cells lacking Plk4 undergo a cell cycle arrest 
We next examined the chronic effect of Plk4 depletion in RPE1 cells. While Plk4+/+ cells 
proliferated normally in the presence of IAA, addition of IAA to Plk4AID/AID cells resulted in a 
cell cycle arrest 48 hours after treatment began (Fig. 5A). Interphase Plk4AID/AID cells exhibited a 
dramatic reduction in centriole number by 24 hours after IAA addition (Fig. 5B). Centriole 
number decreased further by 48 hours after Plk4 degradation, giving rise to 22% of cells that 
lack centrioles. After this time, centriole content changed only slowly, consistent with the fact 
that the vast majority of cells cease proliferating by 48 hours after IAA addition. 
 
To evaluate the long-term growth potential of cells that lack endogenous Plk4, we performed 
clonogenic survival assays. IAA addition prevented colony formation in Plk4AID/AID cells, but 
only modestly affected the survival of Plk4+/+ and Plk4+/AID cells (Fig. 4A-B). To determine 
whether Plk4 depletion leads to an irreversible cell cycle arrest, we treated Plk4AID/AID cells with 
IAA for either one hour or four days and then restored Plk4 levels by washing out IAA. While 
one hour of IAA treatment had no affect on cell growth, washout of IAA after 4 days of 
treatment was unable to restore cell proliferation (Fig. 5C). We conclude that chronic depletion 
of Plk4 leads to an irreversible cell cycle arrest. 
 
To examine the effect of centriole loss on cell division, we created Plk4AID/AID cells co-
expressing TagRFP-tubulin, EGFP-Histone H2B, and EGFP-Cep63 [to mark parental centrioles 
(Sir et al., 2011)] and monitored cells by time-lapse microscopy. Untreated control cells 
progressed though mitosis with an average time of 44 minutes and contained a single EGFP-
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Cep63 focus at each spindle pole (Fig. 5D,G). In the first 24 hours after Plk4 destruction, all 
cells formed bipolar spindles and divided normally, albeit with a modest mitotic delay (average 
time of 58 minutes to divide) (Fig. 5D,E). However, by the second day after IAA addition the 
duration of mitosis increased to an average time of 84 minutes (Fig. 5D). Nevertheless, all cells 
progressed to anaphase and successfully executed cytokinesis (Fig. 5E). Although there was an 
increase in chromosome segregation errors in auxin-treated cells, the frequency of these errors 
was too small to account for the growth arrest (Fig. 5E). Interestingly, in a significant fraction of 
divisions, multi-lobed nuclei formed after apparently normal anaphase chromosome movements 
(Fig. 5F-G). Importantly, these cell division defects were not caused by drug treatment alone, as 
IAA had little effect on mitotic timing or nuclear shape in Plk4+/+ RPE1 cells (Fig. 4C-D). 
 
2.6   The cell cycle arrest following centriole duplication failure is not caused 
by a prolonged mitosis.  
Using fixed imaging, we examined the number of centrioles at various time points after IAA 
treatment. As expected, untreated control cells divided with two centrioles at each spindle pole 
(Fig. 6A-B). By contrast, at one day after IAA addition, > 90% of Plk4AID/AID cells divided with 
a single centriole at each spindle pole, while at days 2 and 3 after IAA addition > 65% of cells 
divided with an asymmetric spindle comprised of an acentriolar pole and a pole containing a 
single centriole (Fig. 6A-B). Cell divisions were rarely observed to take place in the absence of 
centrioles. 
 
Previous work has shown that prolonging prometaphase to > 90 minutes leads to a durable G1 
arrest in RPE1 cells (Uetake and Sluder, 2010). We therefore investigated whether an increased 
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mitotic duration could account for the cell cycle arrest observed after centriole duplication 
failure. We first set out to determine the window of tolerance for prometaphase duration in 
Plk4AID/AID cells. Plk4AID/AID cells were treated with 0.08 µM nocodazole for 6 hours and the 
proliferative fate of daughter cells monitored using time-lapse microscopy. Similar to the 
parental RPE1 cells, prolonging the duration of prometaphase in Plk4AID/AID cells to > 97 minutes 
caused a cell cycle arrest in all resulting daughters (Fig. 7A). Addition of IAA to parental RPE1 
cells shortened the window of prometaphase tolerance to 60 minutes (Fig. 7B). Consequently, 
we considered 60 minutes to be the prometaphase threshold for IAA-treated cells. 
 
We next traced the lineage of individual Plk4AID/AID cells treated with IAA (Fig. 7C). Only cells 
that entered the first division within 6 hours of IAA addition were considered in our analysis. As 
a consequence, the first mitosis nearly always occurred with two centrioles at each spindle pole 
and all daughter cells continued to proliferate (Fig. 6B-C). In subsequent divisions, centriole 
number was successively reduced as expected from failed centriole duplication and continued 
cell growth. 48% of daughter cells arrested after the second mitosis, while 78% of daughters 
arrested after the third mitosis and all daughter cells arrested after the fourth mitosis (Fig. 6C). 
The delayed growth arrest after Plk4 destruction strongly suggests that a stress associated with a 
failure of centriole duplication, not loss of Plk4 per se, is responsible for the proliferative arrest.  
 
In the second division after Plk4 destruction, nearly all daughters of mothers that spent > 60 
minutes in prometaphase arrested as expected (Fig. 6D). However, 37% of the daughters of 
mothers that spent < 60 minutes in prometaphase also arrested and this fraction increased to 52% 
and 100% in the third and fourth divisions, respectively. It was previously shown that continuous 
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inhibition of p38 MAPK activity with the small molecule SB203580 overcame the proliferative 
block caused by a prolonged prometaphase induced by transient nocodazole treatment. However, 
inhibition of p38 MAPK activity did not prevent or delay the cell cycle arrest caused by Plk4 
loss (Fig. 7D). We conclude that the cell cycle arrest caused by centriole duplication failure is 
not simply due to a prolonged prometaphase duration (Uetake and Sluder, 2010). 
 
Previous work has shown that DNA damage, Hippo pathway activation or excessive oxidative 
stress can cause a cell cycle arrest (Ganem et al., 2014). However, addition of IAA for three days 
did not lead to a detectable increase in DNA damage (measured by γH2A.X phosphorylation) or 
Hippo pathway activation (revealed by LATS2 or YAP phosphorylation) in Plk4AID/AID cells 
(Fig. 6E). In addition, culturing Plk4AID/AID cells in 3% O2, rather than 21% O2, did not prevent 
the proliferative arrest following Plk4 destruction (Fig. 6F). Taken together, our data suggest that 
DNA damage, Hippo pathway activation, and oxidative stress are unlikely to be the cause of the 
cell cycle arrest that occurs following a failure of centriole duplication. 
 
2.7   Repression of p53 allows Plk4-depleted cells to proliferate and become 
acentriolar 
RPE1 cells maintain a normal p53-response. Plk4AID/AID cells but not Plk4+/+ cells showed 
stabilization of p53 at two and three days after IAA addition (Fig. 8A). We therefore tested 
whether stabilization of p53 contributes to the irreversible cell cycle arrest that occurs following 
Plk4 depletion and centriole duplication failure. Preventing p53 accumulation using a stably 
expressed p53 shRNA (Fig. 8B) allowed the continued growth of cells lacking Plk4 (Fig. 9A) 
and led to a partial recovery of the clonogenic survival of this population (Fig. 8C-D). Our 
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findings indicate that a failure of centriole duplication increases p53 levels, eliciting a p53-
dependent cell cycle arrest. This is consistent with prior work showing that knockout cells 
lacking proteins essential for centriole duplication also fail to proliferate in the presence of p53 
(Bazzi and Anderson, 2014; Izquierdo et al., 2014). 
 
Plk4AID/AID;p53 shRNA cells proliferated indefinitely in the absence of Plk4, and by 6 days after 
IAA addition Centrin foci were undetectable in > 90% of cells (Fig. 9B-C). To confirm that 
chronically treated Plk4AID/AID;p53 shRNA cells lacked centrioles, we performed 
immunostaining for a variety of centriole components (CPAP, SAS6, STIL, CEP135, CEP152, 
CEP192), but failed to observe centriole foci in the vast majority of cells (data not shown). We 
therefore used thin-section electron microscopy to evaluate the presence of centrioles.  While 
centrioles were identified in 37/138 transverse sections of control cells, we never observed 
centrioles in 320 sections from chronically IAA-treated cells. Thus, the failure to detect Centrin 
foci almost certainly reflects an absence of centrioles in the vast majority of chronically treated 
Plk4AID/AID;p53 shRNA cells (hereafter referred to as acentriolar cells). Consistent with a lack of 
centrioles, the PCM component γ-tubulin was diffusely localized throughout the cytosol of 
interphase cells lacking centrioles and failed to concentrate at acentriolar spindle poles (Fig. 9C). 
However, 55% of interphase acentriolar cells contained a single focus of the PCM component 
Pericentrin, suggesting that Pericentrin may have the capacity to self-organize in the absence of 
centrioles (Fig. 8E). 
 
To directly examine the divisions of cells lacking centrioles, acentriolar cells co-expressing 
TagRFP-tubulin, EGFP-Histone H2B and EGFP-Cep63 were monitored by time-lapse 
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microscopy. Untreated Plk4AID/AID;p53 shRNA cells entered mitosis with two microtubule asters 
and assembled robust bipolar spindles (Fig. 9E). By contrast, in acentriolar cells microtubule 
nucleation occurred randomly around the chromatin, before self-organizing into a bipolar spindle 
with Pericentrin, but not γ-tubulin, concentrated at the poles (Fig. 9C,E; Fig. 8E). Acentriolar 
divisions exhibited an increased mitotic duration (average of 147 minutes, compared with 42 
minutes for untreated cells) and were associated with a higher frequency of chromosome 
segregation errors (40% in acentriolar cells vs 17% in control cells) and cytokinesis failure (22% 
in acentriolar cells vs 1% in control cells) compared with untreated control Plk4AID/AID;p53 
shRNA cells (Fig. 9D). Consistent with the increased incidence of cytokinesis failure, a sub-
population of acentriolar cells contained a tetraploid DNA content (Fig. 8F). These mitotic errors 
are likely to be the cause of the reduced growth rate and increased doubling time of acentriolar 
cells (Fig. 9A, Fig. 8G). These data are in accord with the view that centrioles are not strictly 
essential for mitosis in vertebrate cells, but increase the fidelity of chromosome segregation and 
cytokinesis (Debec et al., 2010; Khodjakov and Rieder, 2001; Sir et al., 2013). 
 
2.8   Restoration of endogenous Plk4 levels in acentriolar cells results in de 
novo centriole formation. 
In vertebrate somatic cells, de novo centriole assembly is initiated following the eradication of 
the existing centrioles by laser ablation or microsurgery (Khodjakov et al., 2002; La Terra et al., 
2005; Uetake et al., 2007). In this case a variable number of de novo centrioles are spontaneously 
generated. We therefore examined the effect of restoring endogenous Plk4 levels in acentriolar 
cells. Endogenous Plk4 levels returned to normal within 12 hours of IAA washout (Fig. 10A) 
and promoted the penetrant formation of de novo centrioles: by two days after IAA washout, de 
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novo centriole assembly occurred in 74% of cells and increased to > 95% of cells by four days 
after IAA removal (Fig. 10B, Fig. 8H). Knockdown of the cartwheel component STIL prevented 
de novo centriole assembly, suggesting that, similar to canonical centriole duplication, de novo 
centrioles assemble through a cartwheel-dependent mechanism (Fig. 10C). Taken together, these 
data show that Plk4 levels are rate limiting for both canonical and de novo centriole assembly. 
 
De novo centriole assembly occurred stochastically throughout the cytosol of cells, resulting in 
the formation of a variable number of centrioles (Fig. 10B, Fig. 8H). While cells with 1-4 de 
novo centrioles always divided normally, cells with supernumerary de novo centrioles underwent 
frequent (6-18%) multi-polar divisions (Fig. 10D-F).  Since the progeny of multi-polar divisions 
are invariably inviable (Ganem et al., 2009), aberrant mitotic divisions are likely to limit the 
proliferative potential of cells with supernumerary de novo centrioles. The decreased growth 
potential of cells with supernumerary centrioles may explain why the fraction of cells with a 
normal centriole number gradually increases in abundance after IAA washout (Fig. 10B).  
 
De novo centriole assembly required cell cycle progression, as arresting cells in G1 phase with 
mimosine or the CDK2/4 inhibitor PD0332991 greatly reduced the frequency of de novo 
centriole formation by two days after IAA washout (Fig. 11A-C) (Fry et al., 2004; Watson et al., 
1991). To examine the composition of de novo centrioles we performed immunostaining for 
several centriole components at 1, 2, 3 and 4 days after IAA washout. By two days after IAA 
washout, Plk4, CPAP, CEP135, CEP152, CEP164 and CEP192 co-localized with at least one 
Centrin-marked, de novo centriole in > 75% of cells (Fig. 10G, Fig. 11D). By contrast, only 40-
55% of cells with de novo centrioles contained centriole-localized STIL or SAS6, consistent with 
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the fact that STIL and SAS6 are absent from centrioles during G1 phase (Arquint and Nigg, 
2014; Arquint et al., 2012; Strnad et al., 2007; Tang et al., 2011). Importantly, all of the de novo 
centrioles observed in transverse sections by EM exhibited a normal morphology, with triplet 
microtubules arranged with nine-fold rotational symmetry (n = 83 total de novo centrioles, 13 of 
which were sectioned transversely and could be assessed for rotational symmetry) (Fig. 12A-B). 
 
To examine the kinetics of de novo centriole assembly, we generated acentriolar cells stably 
expressing EGFP-Centrin and performed time-lapse imaging following IAA washout. 
Approximately 9 hours prior to mitosis, a variable number of EGFP-Centrin foci formed 
dispersed throughout the cytosol (Fig. 13A-B). These foci increased in size and intensity until 
they were indistinguishable from EGFP-Centrin foci observed at normal centrioles in control 
cells. Immunofluorescence staining showed that the newly formed Centin foci co-localized with 
CEP192 and are thus likely to represent de novo centrioles (Fig. 13C). Once de novo centrioles 
had formed, no additional Centrin foci were generated, consistent with the observation that de 
novo centriole assembly is inhibited by the presence of centrioles (Fig. 13A) (La Terra et al., 
2005; Marshall et al., 2001). To test if a single centriole is capable of suppressing de novo 
centriole formation, we transiently treated EGFP-Centrin expressing Plk4AID/AID;p53 shRNA 
cells with IAA to generate a fraction of cells with a single centriole, then removed IAA and 
monitored de novo centriole formation by time lapse microcopy. Strikingly, while 80% of 
acentriolar cells underwent de novo centriole formation within 36 hours of IAA washout, only 




In the first mitotic division after IAA washout, the majority of single de novo centrioles 
segregated on the mitotic spindle (Fig. 13D). After the first division, de novo centrioles clustered 
to a single location. Later in the cell cycle, centrioles dispersed around the nuclear envelope and 
underwent duplication, with each single EGFP-Centrin focus becoming a duplex of two 
centrioles (Fig. 13A,C). Pairs of Centrin foci always contained a single focus of the proximal 
centriole marker CNAP1, consistent with an engaged “mother-daughter” configuration (Fig. 
13E). CEP164 is a distal appendage protein that usually marks the mature mother centriole 
(Graser et al., 2007). Surprisingly, however, duplicated pairs of de novo centrioles did not always 
contain a CEP164-positive centriole (Fig. 11F). By two days after IAA washout, duplicated 
centriole pairs recruited PCM material and acted as MTOCs (Fig. 13D). We conclude that the de 
novo centrioles are functionally indistinguishable from canonical centrioles. 
 
2.9   Discussion 
In this study, we have developed a chemical genetic approach to reversibly deplete Plk4 and 
centrioles in a proliferating population of human cells. This is the first time the auxin-inducible 
destruction system has been used to reversibly manipulate the levels of an endogenous protein in 
vertebrate cells. In principle, the strategy we have taken could be applied to control the levels of 
many proteins that are not amenable to traditional chemical inhibition. In the future, combining 
the AID-system with CRISPR/Cas9 genome engineering will greatly increase the efficiency with 
which bi-allelic targeting of endogenous genes can be achieved, paving the way for rapid and 
tunable control of protein function. 
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The long-term consequence of centriole depletion has not been studied in a non-transformed 
vertebrate cell line. By inducing chronic depletion of Plk4, we reveal the presence of a p53-
dependent pathway that arrests the growth of untransformed cells following a failure of centriole 
duplication (Fig. 9A). Furthermore, by exploiting the reversibility of Plk4 depletion, we show 
that the cell-cycle arrest caused by centriole loss is irreversible (Fig. 5C). A recent study arrived 
at similar conclusions using a potent inhibitor of Plk4 kinase activity to deplete centrioles from 
proliferating cells (Wong et al., 2015a). Mouse embryos lacking the essential centriole protein 
CPAP lack centrioles and cilia and die during midgestation due to widespread p53-dependent 
apoptosis (Bazzi and Anderson, 2014). Similarly, deletion of CPAP in the developing mouse 
brain also resulted in increased cell death, which was rescued by removal of p53 (Insolera et al., 
2014). The contrast between the apoptotic response in mouse embryos and the arrest we 
observed in human cells suggests that embryonic and adult cell types have different proclivities 
for initiating apoptosis or senescence after centriole loss. Interestingly, in contrast to the situation 
in mouse and human cells, Drosophila cells lacking centrioles do not arrest or die (Basto et al., 
2006; Lecland et al., 2013), suggesting that cell-cycle checkpoints for eliminating acentriolar 
cells are more stringent in vertebrates. 
 
While mouse embryos proceed through many cell divisions without centrioles before initiating 
apoptosis, we found that many human somatic cells ceased dividing prior to the total loss of 
centrioles (Fig. 6B). Importantly, we did not observe detectable increases in Hippo pathway 
activation, DNA damage or cytokinesis failure in the 2-3 cell cycles that occur after Plk4 
degradation (Fig. 5E and 6E). We did, however, observe an increase in chromosome segregation 
errors in cells with a reduced centriole number (9% at day 1, 19% at day 2, and 14% at day 3 
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after IAA addition) (Fig. 5E). While chromosome segregation errors can lead to a p53-dependent 
arrest (Thompson and Compton, 2010), the frequency of these errors was too low to account for 
the reduction in proliferation after Plk4 loss (Fig. 5E). In mouse embryos that lack centrioles, the 
stabilization of p53 was proposed to arise as a result of a modest (~10 minute) increase in mitotic 
duration (Bazzi and Anderson, 2014). However, using single-cell lineage tracing, we show that 
an extended mitosis cannot, by itself, explain the cell cycle arrest that occurs in human cells that 
fail centriole duplication (Fig. 6D). Further investigation will therefore be required to establish 
the underlying cause of the proliferative arrest that occurs following Plk4 loss. 
 
Removal of p53 allowed human cells to proliferate indefinitely despite the absence of centrioles 
(Fig. 9A). As centrosomes increase the speed of spindle assembly, these acentriolar cells formed 
bipolar spindles at a considerably slower rate than cells containing centrioles. In addition, 
acentriolar cells displayed chromosomal instability and frequent cytokinesis failure (Fig. 9D). 
Similar mitotic errors have been reported in acentriolar Drosophila cells and transformed 
vertebrate cell lines, highlighting the important role of centrioles in ensuring the fidelity of cell 
division in adult cells (Basto et al., 2006; Debec et al., 2010; Khodjakov and Rieder, 2001; Sir et 
al., 2013). Surprisingly, however, acentriolar mouse embryos showed no detectable increase in 
chromosome segregation errors (Bazzi and Anderson, 2014). The first five rounds of cell 
division in the mouse embryo are naturally acentriolar (Szollosi et al., 1972) and it is therefore 




Overexpression of Plk4 did not promote de novo centriole formation in acentriolar mouse 
zygotes (Coelho et al., 2013), but was capable of inducing de novo centriole formation in 
unfertilized fly eggs (Peel et al., 2007; Rodrigues-Martins et al., 2007) and activated Xenopus 
oocytes (Eckerdt et al., 2011). Here we have shown that restoring endogenous levels of Plk4 
induces de novo centriole formation in acentriolar human somatic cells. We speculate that de 
novo centrioles are created from Plk4 foci that form stochastically in the cytosol of acentriolar 
cells (Fig. 11G). Once these foci surpass a threshold level of Plk4 activity, cartwheel assembly 
would be initiated, leading to centriole formation. Consistent with this idea, we were able to 
observe recruitment of the cartwheel components STIL and SAS6 to Plk4 foci as an early event 
occurring prior to incorporation of Centrin into de novo centrioles (Fig. 11G).  
 
De novo centrioles assembled very efficiently (within 2-3 cell cycles) following restoration of 
Plk4 levels (Fig. 10B). This is in accordance with the previous work examining the kinetics of de 
novo centriole formation in somatic human cells (La Terra et al., 2005; Uetake et al., 2007) and 
green algae (Marshall et al., 2001). Procentrioles formed in S phase are normally modified 
during mitosis to activate their ability to recruit PCM material and function as MTOCs in the 
next cell cycle (Wang et al., 2011). In our experiments, cells that lack centrioles undergo a 
prolonged prometaphase, providing increased time for newly created de novo centrioles to be 
modified and converted into MTOCs. Consistently, we observed that in the first cell cycle, the 
vast majority of de novo centrioles recruited small amounts of PCM material in mitosis and were 
capable of segregating themselves on the mitotic spindle (Fig. 13D). De novo centrioles 
duplicated in the second cell cycle after their creation, consistent with a previous report 
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demonstrating that newly formed centrioles are modified in mitosis to license their duplication 
(Fig. 13A,D) (Wang et al., 2011).  
 
A single centriole was shown to suppress de novo centriole assembly in the vast majority of 
cells, supporting the conclusion that existing centrioles inhibit the de novo assembly pathway 
(Fig. 11E) (La Terra et al., 2005; Marshall et al., 2001). Like canonical centriole assembly, de 
novo centriole formation requires Plk4 activity (Wong et al., 2015b). An intriguing possibility, 
therefore, is that existing centrioles sequester an activator of Plk4 and thereby act to inhibit the 
cytosolic pool of Plk4 and suppress de novo centriole formation. The ability to induce timed de 
novo centriole biogenesis in populations of cycling acentriolar cells offers an excellent tool to 
dissect the molecular events involved in centriole formation and how centrioles antagonize the 
de novo pathway. 
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2.10   Figures and Legends 
 
Figure 1. Generation of Plk4AID/AID cells. 
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(A) Schematic outlining the strategy for the construction of Plk4AID/AID RPE1 cells.  
(B) Genotyping of Plk4-AID heterozygous and homozygous cells. Plk4AID/AID cells possess a 
single band corresponding to the Plk4-AID allele. 
(C) Quantification of the number of γ-tubulin foci in Plk4+/+ and Plk4AID/AID cells. Each bar 
represents the mean of > 100 cells from at least two independent experiments. Error bars 
represent the S.E.M.  
(D) Flow cytometry cell cycle analysis showing normal asynchronous cell cycle profiles for 
Plk4+/+ and Plk4AID/AID cells.  
(E) Selected images of Plk4AID/AID cells immunostained for Plk4, FLAG and HA. HA, FLAG and 
Plk4 antibody signals co-localize in interphase and mitotic cells. Scale bars: 5 µm (main); 1 µm 
(inset). 
(F) Quantification of the level of Plk4 at the centrosome at the indicated times after IAA 
addition. Each condition represents the mean of > 70 cells from at least two independent 
experiments. Error bars represent the S.E.M. 
(G) Selected images of untreated control or IAA-treated cells immunostained with CEP192, Plk4 
and Myc. 4 days after IAA addition, CEP192 and Plk4 are no longer detectable in cells 
expressing the F-box protein osTIR1-9Myc, but are present in neighboring cells lacking osTIR1-




Figure 2. Inducible destruction of endogenous Plk4.  
(A) Schematic outlining the strategy for the auxin-inducible destruction of Plk4.  
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(B) Western blot showing the levels of immunoprecipitated Plk4-AID-FLAG at the indicated 
times after IAA addition.  
(C) Plk4AID/AID cells immunostained for CEP192, Plk4 and FLAG after treatment with IAA for 
the indicated time. Scale bars: 5 µm (main); 1 µm (inset). 
(D) Quantification of the level of FLAG-tagged Plk4-AID at the centrosome at the indicated 
times after IAA addition. Each condition represents the mean of > 70 cells from at least two 
independent experiments.  
(E) Quantification of the level of FLAG-tagged Plk4-AID at the centrosome at the indicated cell 
cycle stages. Horizontal line represents the mean of > 70 cells from two independent 
experiments.  
(F) Quantification of Plk4 protein levels at the centrosome at the indicated time after IAA 
washout. Plk4 levels return to normal within 3 hours of auxin removal. Each bar represents the 
mean of > 70 cells from at least two independent experiments. All error bars in the figure 




Figure 3. The centriole localization of STIL requires Plk4. 
(A) Quantification of Plk4 protein levels at the centrosome of interphase cells at 24 hours after 
addition of the indicated concentrations of IAA (grey bars). The fraction of mitotic cells that 
underwent successful centriole duplication (≥ 3 centrioles) was quantified in the same samples 
(open bars). Bars represent the mean of > 40 cells from two independent experiments.  
(B) Representative images of Plk4AID/AID cells immunostained with CEP192 and Centrin after 
treatment with the indicated dose of IAA for 24 hours. Scale bars: 5 µm (main); 1 µm (inset). 
(C) Quantification of relative protein abundance at the centrosome of S or G2 phase (CENP-F 
positive) cells 1 hour after IAA addition. Centriole recruitment of STIL requires Plk4. r-SAS6 = 
rabbit SAS6 antibody; m-SAS6 = mouse SAS6 antibody. Bars represent the mean of > 35 cells 
from two independent experiments. Immunoblot shows no change in the level of endogenous 




Figure 4. Destruction of Plk4 leads to a long-term growth arrest. 
(A) Representative images of crystal violet stained colonies formed two weeks after addition of 
IAA.  
(B) Quantification of the percent clonogenic survival of the indicated cell lines. Bars represent 
the mean of at least two independent experiments carried out in triplicate. 
(C) – (D) Quantification of mitotic duration and the frequency of divisions resulting in the 
formation of misshapen nuclei in IAA-treated Plk4+/+ cells. IAA has a negligible impact on 




Figure 5. Plk4 depletion leads to a failure of centriole duplication followed by a cell-cycle 
arrest. 
(A) Graph showing the fold increase in cell number after IAA addition. Plk4 destruction leads to 
a cell-cycle arrest in Plk4AID/AID cells. Points show the mean of at least two independent 
experiments performed in triplicate. 
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(B) Quantification of the number of Centrin foci per cell in interphase at indicated times after 
IAA addition. Bars represent the mean of > 100 cells from two independent experiments. 
(C) Graph showing the fold increase in cell number after IAA washout (WO) and restoration of 
Plk4 levels. Centriole loss leads to an irreversible cell-cycle arrest. Points show the mean of at 
least two independent experiments performed in triplicate. 
(D) Quantification of the duration of mitosis. Measurements were taken over a 24-hour period at 
indicated times after IAA addition. Bars represent the mean of > 60 cells from two independent 
experiments.  
(E) Quantification of relative cell proliferation and fraction of cells undergoing chromosome 
missegregation or cytokinesis failure. Measurements were taken over a 24-hour period at 
indicated times after IAA addition. Bars represent the mean of > 40 cells from two independent 
experiments.  
(F) Quantification of the frequency of divisions resulting in the formation of misshapen nuclei. 
Measurements were taken over a 24-hour period at indicated times after IAA addition. Bars 
represent the mean of > 40 cells from two independent experiments. All error bars in the figure 
represent the S.E.M.  
(G) Selected images from a time-lapse series of untreated or IAA-treated Plk4AID/AID cells co-
expressing histone TagRFP-Tubulin, EGFP-Histone H2B and EGFP-CEP63. Insets show EGFP-
CEP63 at the centrosome. Time is indicated in minutes relative to nuclear envelope breakdown 
(time point 0). Note that the cell treated with IAA for 2 days exhibits an asymmetric spindle with 
one acentriolar pole. The interphase nucleus labeled with an asterisk at 189 min later left the 




Figure 6. The IAA-induced cell-cycle arrest is not caused by a prolonged mitosis. 
(A) Representative images of anaphase cells at indicated times after IAA addition. Cells were co-
stained with Centrin and CEP192. Scale bars: 5 µm (main); 0.5 µm (inset). 
(B) Quantification of the percentage of cell divisions occurring with the indicated number of 
centrioles at each spindle pole. Measurements were obtained from fixed samples at the indicated 
times after IAA addition. Bars represent the mean of > 60 cells from two independent 
experiments. 
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(C) Schematic showing the expected dynamics of centriole dilution following IAA treatment. 
Cells that undergo mitosis within 6 hours of IAA addition almost always contain 4 centrioles, 
which dilute out as shown in subsequent divisions. 
(D) Graph showing the prometaphase duration and proliferative capacity of IAA-treated 
Plk4AID/AID cells. Each bar represents a daughter cell; its height represents the prometaphase 
duration of the mother cell, and its color represents the fate of the daughter. Only cells that 
underwent their first mitosis within 6 hours of IAA treatment were analyzed. The dashed red line 
indicates the maximum time that IAA-treated cells spend in prometaphase before undergoing a 
cell cycle arrest (See Supplemental Figure S3D). Data is taken from two independent 
experiments (n=199 prometaphases). 
(E) Immunoblot showing the levels of phosphorylated LATS, YAP and Histone H2AX in IAA-
treated Plk4AID/AID and parental RPE1 cells. Doxorubicin treatment was used as a control to 
induce DNA damage. 
(F) Graph showing the fold increase in cell number in IAA-treated Plk4AID/AID cells grown in 
normal (21%) or low (3%) oxygen conditions. Points show the mean of two independent 




Figure 7. Inhibiting the activity of p38 MAPK does not prevent the cell cycle arrest caused 
by centriole duplication failure. 
(A-B) Graph showing the prometaphase duration and proliferative capacity of Plk4AID/AID cells or 
parental RPE1 cells. Each bar represents a daughter cell; its height represents the prometaphase 
duration of the mother cell, and its color represents the fate of the daughter. The dashed red line 
indicates the maximum time that cells spend in prometaphase before undergoing a cell cycle 
arrest. 
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Plk4AID/AID cells were treated with 0.08 µM Nocodazole for the first 6 hours of imaging, while 
IAA was administered to parental RPE1 cells throughout the experiment. Data were acquired in 
a single experiment (n=87 and n=77 prometaphases, respectively) 
(C) Example lineages taken from the analysis presented in Figure 4D. Note that daughter cells 
can undergo symmetric or asymmetric fates. 
(D) Cells were analyzed as in (A-B). Only cells that underwent their first mitosis within 6 hours 
of IAA treatment were analyzed. IAA and SB203580 were administered throughout the 




Figure 8. Cell cycle progression and spindle assembly in the absence of centrioles. 
(A) Quantification of the relative level of nuclear p53 in fixed samples at the indicated times 
after IAA addition. p53 levels increase following Plk4 degradation. Bars represent the mean of > 
200 cells from at least two independent experiments. 
(B) Immunoblot showing the level of p53 in doxorubicin-treated cells.  
(C) Representative images of crystal violet stained colonies formed two weeks after addition of 
IAA.  
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(D) Quantification of the percent clonogenic survival of the indicated cell lines. p53 knockdown 
partly rescues the clonogenic survival of cells lacking Plk4. Bars represent the mean of at least 
two independent experiments carried out in triplicate. All error bars in the Figure represent the 
S.E.M. 
(E) Representative images of untreated control or acentriolar cells immunostained with α-
Tubulin, Pericentrin and Centrin. Scale bars: 5 µm (main); 1 µm (inset). 
(F) Flow cytometry cell cycle analysis showing an increase in polyploidy in acentriolar cells. 
(G) Table displaying the doubling time of the indicated cell lines in the presence and absence of 




Figure 9. Depletion of p53 allows continued growth in the absence of Plk4. 
(A) Graph showing the fold increase in cell number after IAA addition. Points show the mean of 
at least two independent experiments performed in triplicate. 
(B) Quantification of the number of Centrin foci per cell in interphase at indicated times after 
IAA addition. Bars represent the mean of > 150 cells from two independent experiments. 
(C) Selected images of untreated control or acentriolar Plk4AID/AID;p53 shRNA cells 
immunostained with α-Tubulin, γ-Tubulin and Centrin. Scale bars: 5 µm (main); 1 µm (inset). 
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(D) Quantification of the duration of mitosis, the frequency of divisions resulting in the 
formation of misshapen nuclei and the frequency of cytokinesis failure and chromosome 
missegregation in acentriolar Plk4AID/AID;p53 shRNA cells. Bars represent the mean of > 100 
cells from two independent experiments. All error bars in the Figure represent the S.E.M. 
(E) Selected images from a time-lapse series of untreated control or acentriolar Plk4AID/AID;p53 
shRNA  cells co-expressing histone TagRFP-Tubulin, EGFP-Histone H2B and EGFP-CEP63. 
Insets show EGFP-CEP63 at the centrosome. The acentriolar cell spends longer in mitosis and 
fails cytokinesis. Time is indicated in minutes relative to nuclear envelope breakdown (time 




Figure 10. Restoration of Plk4 levels in acentriolar cells leads to de novo centriole 
formation. 
(A) Immunoblot showing the level of immunoprecipitated endogenous Plk4-AID-FLAG at the 
indicated times after IAA washout in acentriolar, Plk4AID/AID;p53 shRNA cells. 
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(B) Quantification of the number of Centrin foci per interphase cell at indicated times after IAA 
washout, in Plk4AID/AID;p53 shRNA cells. Bars represent the mean of > 200 cells from three 
independent experiments. 
(C) (Top) Quantification of the number of Centrin-marked de novo centrioles in interphase cells 
at 2 days after IAA washout (WO). Cells were transfected with the STIL siRNA 24 hours prior 
to IAA washout. (Bottom) Immunoblot showing depletion of STIL at 48 hours after transfection 
with STIL siRNA.  
(D-E) Quantification of the fraction of bipolar and multipolar divisions in Plk4AID/AID;p53 
shRNA at indicated times after IAA washout. Bars represent the mean of > 120 cells from two 
independent experiments. All error bars in the Figure represent the S.E.M. 
(F) Selected images of anaphase phenotypes. Both single and pairs of de novo centrioles 
clustered at the poles of the mitotic spindle. Cells were co-stained with Centrin and CEP192. 
Scale bars: 5 µm (main); 1 µm (inset). 
(G) Selected images of Centrin-marked de novo centrioles at 1 day after IAA washout. Cells 
were co-stained with Plk4, STIL, SAS6, CPAP, CEP192, CEP152 and CEP135. Scale bars: 5 µm 




Figure 11. De novo centriole formation requires cell cycle progression. 
(A) Quantification of the fraction of EdU-positive cells. Measurements were made two days after 
release from IAA in the presence or absence of mimosine or PD0332991. Bars represent the 
mean of > 30 cells. 
(B) Quantification of the fraction of Centrin foci in interphase cells. Measurements were made 
two days after release from IAA in the presence or absence of mimosine or PD0332991. Bars 
represent the mean of > 30 cells. 
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(C) Selected images of control untreated and mimosine treated cells at 2 days after IAA washout. 
Cells were co-stained with DAPI and EdU. Scale bars, 20 µm. 
(D) Quantification of the fraction of interphase cells with Centrin-marked de novo centrioles that 
co-localize with the indicated centriole components. Quantification was derived from fixed 
images taken 1, 2, 3 and 4 days after IAA washout. Bars represent the mean of > 40 cells from 
two independent experiments. 
(E) Quantification of the fraction of cells that underwent de novo centriole formation. Acentriolar 
and single centriole-containing cells expressing EGFP-Centrin were tracked for 60 hours by 
time-lapse microscopy. Bars represent the mean of two independent experiments. All error bars 
in the Figure represent the S.E.M. 
(F) Image of de novo centrioles at 3 days after IAA washout. Cells were co-stained with 
CEP164, CNAP1 and Centrin. Scale bars: 5 µm (main); 1 µm (inset). 
(G) Selected images of control de novo centrioles at 1 day after IAA washout. Cells were co-
stained with Centrin, Plk4 and STIL. Plk4 and STIL form foci that do not co-localize with 
Centrin and likely represent sites of nascent de novo centriole formation. Scale bars: 5 µm 




Figure 12. De novo formed centrioles have a normal structure. 
(A) – (B) Thin section transmission electron micrographs of (A) existing centrioles or (B) de 





Figure 13. De novo centrioles recruit PCM and act as MTOCs.  
(A) Selected images from a time-lapse series showing de novo centriole formation in cells 
expressing histone EGFP-Centrin. De novo centrioles duplicate in the second cycle after they are 
born. Time is indicated in hours relative to the time of IAA washout (time point 0). Scale bars: 5 
µm (main); 1 µm (inset). 
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(B) Quantification of the time of de novo centriole formation relative to the time of cell division. 
Measurements were made using time-lapse movies of EGFP-Centrin expressing cells from two 
independent experiments. Line represents the mean of > 50 cells. 
(C) Selected images illustrating the different configurations adopted by de novo centrioles. Cells 
were co-stained with Centrin and CEP192 to identify centrioles. Scale bars: 5 µm (main); 1 µm 
(inset). 
(D) Selected images of de novo centrioles in interphase and mitotic cells at 1 and 2 days after 
IAA washout. The mitotic spindle segregates freestanding de novo centrioles in the first division 
and pairs of replicated centrioles in the second cell division. Cells were co-stained with α-
Tubulin, Centrin and γ-Tubulin or Pericentrin. Scale bars: 5 µm (main); 1 µm (inset). 
(E) Selected images of pairs of de novo centrioles in interphase cells at 2 days after IAA 







Identification of a mitotic surveillance 
pathway 
Modified from: Lambrus BG*, Daggubati V*, Uetake Y, Scott PM, Clutario KM, Sluder G, 
Holland AJ. (2016) A USP28–53BP1–p53–p21 signaling axis arrests growth after centrosome 
loss or prolonged mitosis. Journal of Cell Biology. doi: 10.1083/jcb.201604054. (*Co-first 
authors). 
3.1   Introduction 
As discussed in the previous chapter, inhibition of Plk4 kinase activity or induced degradation of 
Plk4 leads to centrosome loss and a p53-dependent cell cycle arrest within a few cell divisions 
(Lambrus et al., 2015; Wong et al., 2015c). This arrest was not due to mitotic errors, Hippo 
pathway activation, p38-mediated stress signaling, or DNA damage (Lambrus et al., 2015; Wong 
et al., 2015c). Genetic inactivation of the centriole protein SAS4 in the mouse embryo or in the 
developing mouse brain also results in centrosome loss, delayed spindle assembly and p53-
dependent apoptosis (Bazzi and Anderson, 2014; Insolera et al., 2014). Together, these studies 
implicate the existence of a new signaling pathway that activates p53 in response to a signal 




While centrosomes are required for the sustained proliferation of non-transformed mammalian 
cells, a wide array of tumor cells are able to continue to proliferate after centrosome loss (Wong 
et al., 2015c). Cell divisions that lack centrosomes are error-prone (Debec et al., 2010; 
Khodjakov and Rieder, 2001; Lambrus et al., 2015; Sir et al., 2013), suggesting that the 
centrosome surveillance pathway could protect against genome instability by preventing the 
growth of cells with too few centrosomes. Nevertheless, it remains unclear how p53 is activated 
in response to centrosome loss in mammalian cells. In this manuscript, we explore the genetic 
basis for signaling through the centrosome surveillance pathway.  
 
3.2   A chemical genetic system to activate the centrosome surveillance 
pathway 
We set out to develop a chemical genetic system to specifically inhibit Plk4 kinase activity and 
induce centrosome loss in human cells. Mutation of a single amino acid in the ATP-binding 
pocket of Plk4 creates an analog-sensitive (AS) kinase that can be inhibited with non-
hydrolyzable, bulky ATP analogs (Fig. 14A) (Holland et al., 2010b; Moyer et al., 2015). We 
used CRISPR/Cas9 to knock-in the Plk4 AS mutation (L89G) into the endogenous Plk4 locus in 
non-transformed hTERT-RPE1 cells (Fig. 14B). A clone was identified carrying a frame-shift, 
knockout mutation in one Plk4 allele and an AS knock-in mutation in the second allele. The 
Plk4AS/- cells (hereafter referred to as Plk4AS) proliferated at the same rate as the parental cells 
and contained normal numbers of centrioles (Fig. 14C-D). As expected, inhibition of Plk4 kinase 
activity with 3MB-PP1 led to an increase in Plk4 levels at the centrosome and a failure of 
centriole duplication (Fig. 15A and 1C).  
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While RPE1 cells proliferated normally in the presence of 3MB-PP1, addition of 3MB-PP1 to 
Plk4AS cells resulted in a penetrant G1 cell cycle arrest after 3 days (Fig. 14D and Fig. 15B). As 
a consequence, centriole loss ceased after 4 days of treatment with 3MB-PP1 (Fig. 14C). To 
evaluate the long-term growth potential of cells that lack Plk4 kinase activity, we performed 
clonogenic survival assays. 3MB-PP1 addition prevented colony formation in Plk4AS RPE1 cells, 
but did not affect the survival of parental RPE1 cells (Fig. 15C). The arrest was not caused by 
oxidative stress, as growth in low oxygen (3% O2) did not allow continued growth following 
centrosome loss (Fig. 15D). A similar growth arrest was previously reported in RPE1 cells that 
lose centrosomes as a result of destruction of endogenous Plk4 or treatment with the ATP-
competitive Plk4 inhibitor centrinone (Lambrus et al., 2015; Wong et al., 2015c). We conclude 
that inhibition of Plk4AS kinase activity provides a system to activate the centrosome surveillance 
pathway in RPE1 cells.  
 
3.3   Genome-scale CRISPR/Cas9 knockout screen to identify components of 
the centrosome surveillance pathway 
To identify novel components of the centrosome surveillance pathway, we used Plk4AS RPE1 
cells to perform a genome-wide, loss-of-function CRISPR/Cas9 screen. We generated Plk4AS 
cells stably expressing the SpCas9 endonuclease and transduced them with a genome-wide 
sgRNA library (Shalem et al., 2014). Knockout libraries of RPE1 Plk4AS cells were cultured in 
the presence of DMSO or 3MB-PP1 for 42 days. Cells that lacked genes required for the 
centrosome surveillance pathway were expected to proliferate in the absence of Plk4 kinase 
activity and enrich in the 3MB-PP1 treated population compared to DMSO treated controls (Fig. 
16A). Deep sequencing revealed that the sgRNA distribution in 3MB-PP1 treated cells was 
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significantly different compared with DMSO treated cells (Fig. 16B). The two highest-ranking 
genes in the screen were p53 and 53BP1 (FDR <0.05.) (Fig. 16C, D and Fig. 15E). Importantly, 
53BP1 interacts directly with p53, but has not been previously implicated in the centrosome 
surveillance pathway (Iwabuchi et al., 1994; Joo et al., 2002).  
 
To confirm 53BP1 as a novel hit, we repeated the CRISPR/Cas9 screen in SpCas9-expressing 
hTERT-RPE1 cells using the Plk4 inhibitor centrinone (Wong et al., 2015c). p53 and 53BP1 
emerged again as the top hits from this screen (FDR <0.05) (Fig. 16E-G). To validate the role of 
53BP1 in the centrosome surveillance pathway, we generated knockouts of p53 and 53BP1 in 
Plk4AS cells. Inactivation of p53 or 53BP1 dramatically increased the clonogenic survival of 
Plk4AS cells treated with 3MB-PP1 (Fig. 16H and 15F). Thus, our unbiased, genome-scale 
screening identified 53BP1 as a novel component of the centrosome surveillance pathway. 
 
3.3.1   53BP1 is required to stabilize p53 following centrosome loss  
Knockout of p53 did not alter the levels of 53BP1 and vice-versa, showing these proteins are not 
required for one another’s stability (Fig. 17A, B). To test whether cells lacking 53BP1 lose 
centrosomes in the absence of Plk4 activity, we examined centriole number in p53 and 53BP1 
knockout Plk4AS cells over the course of a week following Plk4 inhibition. Treatment of p53-/- or 
53BP1-/- Plk4AS cells with 3MB-PP1 led to a gradual reduction in centriole number as cells failed 
centriole duplication, but continued to divide. At 6 days after 3MB-PP1 treatment, >90% of p53 
and 53BP1 knockout cells lacked centrioles (Fig. 17C-D). 
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Centrosome loss increased total cellular and nuclear p53 levels (Fig. 17E and 18A). Importantly, 
knockout of 53BP1 prevented p53 stabilization in response to centrosome loss, suggesting that 
53BP1 functions upstream of p53 in the centrosome surveillance pathway (Fig. 17F and 18A). 
Knockout of 53BP1 did not, however, prevent stabilization of p53 in response to doxorubicin-
induced DNA damage (Fig. 18A), showing that 53BP1 is not required for all p53-dependent 
responses.  
 
3.3.2   USP28 functions together with 53BP1 to stabilize p53 following centrosome loss 
We considered the possibility that during the selection period for the CRIPSR/Cas9 screen, 
sgRNAs that provide a modest growth advantage in cells lacking centrosomes may be 
outcompeted by the faster growth of cells containing sgRNAs targeting p53 or 53BP1. To 
investigate whether weaker hits may have been overlooked, we created knockouts for the top 40 
ranked genes and analyzed the ability of each sgRNA to promote the growth of Plk4AS cells in 
the presence of 3MB-PP1 (Fig. 14E). Other than p53 and 53BP1, USP28 (ranked #29) was the 
only other sgRNA target that provided a significant growth advantage in Plk4AS cells grown in 
3MB-PP1 (Fig. 17G-H and 15E-F). Importantly, USP28 is a deubiquitinating enzyme that has 
been shown to interact with 53BP1 (Zhang et al., 2006). 
 
Knockout of USP28 did not alter basal levels of p53, or prevent p53 stabilization in response to 
doxorubicin-induced DNA damage (Fig. 16I, 18A-B). However, USP28-/- cells failed to stabilize 
p53 in response to centrosome loss (Fig. 17J and 18A). Cell lacking USP28 grew continually in 
the absence of Plk4 activity and consequently >90% of USP28 knockout cells lacked centrioles 
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after 6 days of 3MB-PP1 treatment (Fig. 17K-L and 18C). These data demonstrate that USP28 
acts together with 53BP1 to stabilize p53 in response to centrosome loss.   
 
To examine whether USP28 or 53BP1 knockout alters basal p53 stability, we examined p53 
levels after cycloheximide addition in USP28-/- and 53BP1-/- cells. Loss of USP28 and 53BP1 did 
not alter basal p53 stability in Plk4AS cells (Fig. 18D). Furthermore, inhibiting p53 binding to 
MDM2 with Nutlin-3 elevated p53 levels to a similar extent in wild type, USP28-/-, and 53BP1-/- 
Plk4AS cells (Fig. 18E). We conclude that USP28 and 53BP1 do not alter p53 regulation by 
MDM2 or modulate basal p53 stability. 
 
Inhibition of Plk4 kinase activity could have consequences in addition to prompting a failure of 
centriole duplication. We therefore tested whether loss of SAS6, a conserved structural 
component required for centriole assembly, also prevents cell growth, and whether this can be 
overcome by inactivating components of the centrosome surveillance pathway (Dammermann et 
al., 2004; Leidel et al., 2005). Consistent with its essential role in cell growth, we were unable to 
generate SAS6 knockout clones in hTERT-RPE1 cells (Fig. 18F). We did, however, identify 
multiple clones of USP28-/-, 53BP1-/- and p53-/- cells that lacked SAS6 and centrosomes. These 
data suggest that centrosome loss, and not loss of Plk4 kinase activity per se, is responsible for 
activating the centrosome surveillance pathway.  
 
3.3.3   p21 acts downstream of p53 in the centrosome surveillance pathway 
The cyclin-dependent kinase inhibitor p21 (CDKN1A) is a transcriptional target of p53 that is 
responsible for promoting a p53-dependent G1 arrest in response to a variety of stress stimuli. 
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Since p21 also emerged as a weak hit in the CRISPR/Cas9 screen (ranked #146) (Fig. 15E), we 
reasoned that p21 could contribute to the p53-dependent cell cycle arrest that occurs following 
centrosome loss. Indeed, p21 levels increased after Plk4 inhibition (Fig. 18A). Knockout of p21 
did not alter p53 abundance or prevent p53 stabilization following centrosome loss, consistent 
with p21 acting downstream of p53 (Fig. 17M-N and 18A). p21 knockout increased the 
clonogenic survival of Plk4AS cells in the presence of 3MB-PP1 (Fig. 17G-H and 15F). In 
addition, p21-/- cells grew continually in the presence of 3MB-PP1 and by 6 days after 3MB-PP1 
treatment, >90% of Plk4AS; p21-/- cells lacked centrioles (Fig. 17L, O and 18C).  
 
3.3.4   The centrosome surveillance pathway is not activated by DNA damage 
As USP28, 53BP1 and p53 have all been shown to play a role in the DNA damage signaling 
pathway, we asked whether cells that fail centrosome duplication acquire DNA damage. We first 
used immunoblotting to examine changes in the abundance of γ-H2AX. While a brief treatment 
with doxorubicin increased γ-H2AX levels, no increase was observed in Plk4AS cells treated with 
3MB-PP1 (Fig. 19A). In addition, doxorubicin-induced DNA damage led to robust 
phosphorylation of the ATM target sites p53 Ser15 and KAP1 Ser824, but phosphorylation of 
these sites was undetectable in Plk4AS cells grown in the presence of 3MB-PP1 (Banin et al., 
1998; Canman et al., 1998; White et al., 2006; Ziv et al., 2006) (Fig. 19A). We next examined 
53BP1 foci formation using immunofluorescence microscopy. While doxorubicin treatment led 
to a >4-fold increase in the number of cells with >5 53BP1 foci, no significant increase in foci 
formation was observed in Plk4AS cells following centrosome duplication failure (Fig. 19B). 




Next, we tested whether proteins that function in the DNA damage pathway are required to arrest 
the cell cycle following centrosome loss. Chronic treatment with the ATM inhibitor KU-55933 
did not prevent a cell cycle arrest following centrosome loss (Fig. 20A-B). Additionally, ATM, 
RNF8, Chk1 and Chk2 are components of the DNA damage response, but knockout of these 
genes did not abolish the centrosome surveillance pathway (Fig. 14E). Importantly, while Chk2-/- 
Plk4AS cells did not proliferate in 3MB-PP1, loss of Chk2 attenuated DNA damage signaling and 
rescued cell growth in doxorubicin (Fig. 19C-E). This suggests that the DNA damage response 
and centrosome surveillance are genetically separable pathways.  
 
The E3 ubiquitin ligase RNF168 is required for the recruitment of 53BP1 to sites of DNA 
double-strand breaks (Doil et al., 2009; Huen et al., 2007; Kolas et al., 2007; Mailand et al., 
2007; Mallette et al., 2012; Mallette and Richard, 2012). We created RNF168 knockout Plk4AS 
cells and confirmed that while 53BP1 is present at normal levels in these cells, it fails to localize 
to sites of DNA damage (Fig. 19F-G). Importantly, RNF168 knockout cells ceased proliferating 
following centrosome loss, demonstrating that localization of 53BP1 to sites of DNA damage is 
not required for it to function in the centrosome surveillance pathway (Fig. 19H). These data 
suggest that 53BP1 plays a DNA damage-independent role in signaling through the centrosome 
surveillance pathway. 
 
Finally, we tested the ability of cells lacking p53, 53BP1 or USP28 to proliferate following 
doxorubicin-induced DNA damage. As expected, treatment of Plk4AS cells with doxorubicin 
dramatically reduced the fraction of cells that entered into S phase, as well as clonogenic survival 
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(Fig. 19I, 20C). While p53-/- cells progressed into S phase and formed colonies in the presence 
of doxorubicin, USP28-/- and 53BP1-/- cells did not. This demonstrates that the DNA damage 
response remains partly intact in cells lacking USP28 and 53BP1. Taken together, our evidence 
strongly indicates that DNA damage is not responsible for activating the centrosome surveillance 
pathway. 
 
3.4   The cell cycle arrest induced by prolonged prometaphase requires the 
same signaling components as the centrosome surveillance pathway 
To evaluate the effect of centrosome loss on mitotic duration, we grew p53-/-, 53BP1-/- and 
USP28-/- Plk4AS cells in 3MB-PP1 for 6 days and measured the length of mitosis in cells that 
lack centrosomes. Loss of centrosomes dramatically extended the duration of mitosis (average of 
153, 129 and 149 minutes in p53-/-, 53BP1-/- and USP28-/- cells, respectively) (Fig. 21A). 
Previous work has shown that prolonging prometaphase to >90 minutes leads to p53-dependent 
arrest in RPE1 cells (Uetake and Sluder, 2010). This suggests that this mitotic timer may be 
dysfunctional in p53-/-, 53BP1-/- and USP28-/- cells. To investigate this possibility, we first set out 
to determine the window of tolerance for prometaphase duration in the Plk4AS RPE1 cells used in 
this study. Plk4AS cells were treated with nocodazole for 6 hours, and following drug washout, 
the proliferative fate of daughter cells monitored by time-lapse microscopy. While 13% of 
daughters whose mothers spent <120 minutes in prometaphase failed to proliferate, prolonging 
the duration of prometaphase to >120 minutes caused a cell cycle arrest in 88% of the resulting 
daughters (Fig. 21A). Although this response is not as robust as reported in unmodified hTERT-
RPE1 cells, the mitotic timer is clearly functioning in Plk4AS cells (Uetake and Sluder, 2010; 
Wong et al., 2015c). 
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We next investigated whether the newly identified components of the centrosome surveillance 
pathway are also required to arrest cells after an increased mitotic duration. Consistent with 
previous work, nearly all p53-/- daughter cells proliferated regardless of the prometaphase 
duration in the preceding division (Fig. 21B) (Uetake and Sluder, 2010). Remarkably, knockout 
of USP28 and 53BP1 almost completely abolished the G1 arrest after a prolonged prometaphase. 
We conclude that the stresses generated by both centrosome loss and an extended prometaphase 
act through the same signaling components to stabilize p53 and cause a cell cycle arrest.  
 
Since the centrosome surveillance pathway and the mitotic timer require the same components, 
we investigated whether activation of the mitotic timer could account for the cell cycle arrest that 
occurs in Plk4AS cells following centrosome loss. To examine the effect of centrosome loss on 
cell division time, we monitored Plk4AS cells by time-lapse microscopy at 1, 2 and 3 days after 
Plk4 inhibition. Untreated control cells progressed though mitosis with an average time of 25 
minutes (Fig. 21C). Mitotic duration increased as cells progressed through successive divisions 
in the absence of Plk4 activity (average of 40 minutes at day 1, 60 minutes at day 2 and 65 
minutes at day 3 after 3MB-PP1 addition). Nevertheless, no mitosis exceeded a duration required 
to activate the mitotic timer (>120 minutes), suggesting that activation of the centrosome 
surveillance pathway cannot be simply explained by an increase in duration of a single division. 
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3.5   Distinct signal transduction cascades activate p53 in response to 
centrosome amplification or centrosome loss 
We previously showed that Plk4 overexpression promotes centrosome amplification and a p53-
dependent cell cycle arrest in hTERT-RPE1 cells (Holland et al., 2012b). We therefore tested 
whether the proteins required to block proliferation following centrosome loss are also required 
to prevent cell growth in the presence of extra centrosomes. While knockout of p53, and to a 
lesser extent p21, allowed for the growth of Plk4 overexpressing cells with supernumerary 
centrosomes, knockout of 53BP1 and USP28 did not (Fig. 20D). A recent study showed that 
extra centrosomes trigger activation of the Hippo pathway kinase LATS2, which in turn 
stabilizes p53 (Ganem et al., 2014).  However, knockout of LATS1 or LATS2 did not prevent 
growth arrest in cells following either centrosome loss or gain (Fig. 20E-F). Taken together, 
these data suggest that distinct signaling pathways activate p53-p21 in response to centrosome 
loss or the presence of excess centrosomes (Fig. 21D). 
 
3.6   Discussion 
Our results reveal the existence of a USP28-53BP1-p53-p21 signaling axis that arrests cell cycle 
progression following centrosome loss. USP28 and p53 both bind to 53BP1 through the tandem 
C-terminal BRCT repeats (Joo et al., 2002; Knobel et al., 2014). We, therefore, speculate that 
53BP1 could recruit USP28 to deubiquitinate and stabilize p53 in response to centrosome loss 
(Fig. 21D). Although DNA breaks trigger p53 activation, several lines of evidence strongly 
suggest that DNA damage is not responsible for activating the centrosome surveillance pathway. 
First, there is no detectable DNA damage in cells that fail centrosome duplication. Second, 
knockout of bona fide DNA damage components, including ATM, Chk1, Chk2, RNF8 and 
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RNF168 do not prevent cell cycle arrest following centrosome loss. Third, preventing 53BP1 
localization to sites of DNA damage prevents DNA damage-dependent functions of 53BP1, but 
does not prevent the growth arrest after a failure of centrosome duplication. Finally, while loss of 
USP28 or 53BP1 prevents activation of p53 in response to centrosome loss, their loss does not 
prevent p53 stabilization and cell cycle arrest in cells treated with the DNA damaging agent 
doxorubicin.  
 
At present the mechanism by which cells ‘sense’ centrosome loss remains unclear. While it is 
possible that the centrosome surveillance pathway directly monitors centrosome number, we feel 
this is unlikely for two reasons. First, p53, 53BP1, and USP28 do not localize to the centrosome 
in RPE1 cells (Fig. 20G). Second, our evidence suggests that there are distinct pathways that 
activate p53 in cells with either too few or too many centrosomes, arguing against a common 
mechanism for detecting the wrong number of centrosomes. We, therefore, favor the 
interpretation that p53 activation is indirectly triggered by a stress associated with cell cycle 
progression following centrosome loss.  
 
We have shown that, as well as being required for the centrosome surveillance pathway, USP28, 
53BP1, and p53 are also required to prevent the growth of cells that delay in mitosis. This raises 
the possibility that the centrosome surveillance pathway is activated by a prolonged mitosis. 
Nevertheless, cells that fail centriole duplication delay in mitosis, but do not exceed a mitotic 
duration in a single division that is sufficient to activate the mitotic timer (Lambrus et al., 2015; 
Wong et al., 2015c). Since cells that fail centrosome duplication typically undergo 3-4 cell 
divisions before they cease proliferating, it is possible that the cumulative stress from successive 
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delayed cell divisions eventually passes a threshold that triggers an arrest in cells failing 
centrosome duplication. Interestingly, 53BP1 localizes to unattached kinetochores in 
prometaphase, suggesting that it could play a signaling role during mitosis (Fig. 20G) (Jullien et 
al., 2002). Determining whether kinetochore localization of 53BP1 is required for the 
centrosome surveillance pathway and mitotic timer is an important area of future work.  
 
3.7   Figures and Legends 
 
Figure 14. Inhibition of analog-sensitive Plk4 leads to centrosome loss and growth arrest.  
(A) Principle of analog-sensitive Plk4 and its inhibition by 3MB-PP1. 
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(B) Schematic of sgRNA and repair template oligo used to knock-in the analog-sensitive 
mutation at endogenous Plk4 genomic loci. sgRNA sequence is highlighted in blue, and edited 
nucleotides are displayed in red.  
(C) Centriole number distribution in interphase Plk4AS cells at time points after addition of 3MB-
PP1. Data are means ± SEM of three independent experiments (N = 3) with >80 cells per 
experiment. 
(D) Fold increase in cell number after 3MB-PP1 addition. Data are means ± SEM (N = 2, 




Figure 15. Inhibition of Plk4 kinase activity activates the centrosome surveillance pathway 
and prevents cell growth. 
(A) Graph showing the relative levels of Plk4 at the centrosomes of interphase cells at various 
times after addition of 3MB-PP1. Data are means ± SEM (N = 2, >20 cells per experiment). 
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(B) Flow cytometry cell cycle analysis of Plk4AS cells after 4 days in DMSO or 3MB-PP1. 
(C) Representative images of crystal violet stained colonies. 
(D) Graph showing the relative clonogenic survival of 3MB-PP1 treated Plk4AS cells grown in 
either 21% or 3% O2. Data are means ± SEM (N = 2, performed in duplicate). 
(E) Table of rank-ordered candidate hits from the CRISPR/Cas9 screen in Plk4AS cells. Genes 
were ordered using the MaGeCK algorithm (Li et al., 2014). The top-most enriched sgRNA was 
used to validate each gene and the % clonogenic survival of 3MB-PP1 treated Plk4AS cells 
expressing each individual sgRNA is shown. In most cases, % clonogenic growth values 
represent the mean of a single sgRNA performed in duplicate. For genes marked with an *, % 
clonogenic growth values represent the mean of at least two independent sgRNAs performed in 
duplicate.  
(F) Graph showing the relative clonogenic survival of 3MB-PP1 treated Plk4AS; p53-/-, Plk4AS; 





Figure 16. A genome-wide CRISPR/Cas9 screen identifies 53BP1 and p53 as components of 
the centrosome surveillance pathway.  
(A) Schematic of the pooled, positive section CRISPR/Cas9 screen used to identify components 
of the centrosome surveillance pathway.  
(B) Graph showing the distribution of individual sgRNAs. Data are means ± SD. 
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(C) Rank-ordered dot plot showing relative enrichment of individual sgRNAs following 3MB-
PP1 treatment.  
(D) Identification of top candidate genes after 3MB-PP1 treatment using the MaGeCK ranking 
p-value analysis.  
(E) Graph showing the distribution of individual sgRNAs. Data are means ± SD. 
(F) Rank-ordered dot plot showing relative enrichment of individual sgRNAs following 
centrinone treatment.  
(G) Identification of top candidate genes after centrinone treatment using the MaGeCK ranking 
p-value analysis.  
(H) Graph showing the relative clonogenic growth of 3MB-PP1 treated Plk4AS cells expressing 
individual sgRNAs. Data are means ± SEM (N = 2, performed in duplicate). Representative 




Figure 17. p21 and USP28 are required for the centrosome surveillance pathway.  
(A-B) Immunoblot showing the level of p53 or 53BP1 in Plk4AS; p53-/- and Plk4AS; 53BP1-/- 
cells. 
 64 
(C-D) Centriole number distribution in interphase Plk4AS; p53-/- and Plk4AS; 53BP1-/- cells at 
times after addition of 3MB-PP1. Data are means ± SEM (N = 3, >80 cells per experiment). 
(E-F) Relative abundance of nuclear p53 in Plk4AS and Plk4AS; 53BP1-/- cells at times after 
addition of DMSO or 3MB-PP1. Data are means ± SEM (N = 3, >180 cells per experiment). 
(G) Relative clonogenic survival of 3MB-PP1 treated Plk4AS cells expressing individual 
sgRNAs. Data are means ± SEM (N = 2, performed in duplicate).  
(H) Representative images of crystal violet stained colonies.  
(I) Immunoblot showing the level of p53 or 53BP1 protein in Plk4AS; USP28-/- cells. 
(J) Relative abundance of nuclear p53 in Plk4AS; USP28-/- cells at times after addition of DMSO 
or 3MB-PP1. Data are means ± SEM (N = 3, >180 cells per experiment). 
(K) Centriole number distribution in interphase Plk4AS; USP28-/- cells at 6 days after addition of 
3MB-PP1. Data are means ± SEM (N = 3, >80 cells per experiment). 
(L) Fold increase in cell number after 3MB-PP1 addition. Data are means ± SEM (N = 2, 
performed in triplicate). 
(M) Immunoblot showing the level of p21 or p53 in Plk4AS; p21-/- cells. 
(N) Relative abundance of nuclear p53 in Plk4AS; p21-/- cells at times after addition of DMSO or 
3MB-PP1. Data are means ± SEM (N = 3, >180 cells per experiment). 
(O) Centriole number distribution in interphase Plk4AS; p21-/- cells at 6 days after addition of 




Figure 18. USP28-/- and 53BP1-/- cells activate p53 in response to DNA damage, but not 
following centrosome loss. 
(A) Immunoblot showing the level of p21 and p53 at times after addition of DMSO or 3MB-PP1.  
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(B) Images showing loss of nuclear USP28 staining in Plk4AS; USP28-/- cells. Scale bar = 5 µm. 
(C) Graph showing the fold increase in cell number after DMSO addition. Data are means ± 
SEM (N = 2, performed in triplicate). 
(D) Immunoblot showing the abundance of p53 in Plk4AS cells at times after cycloheximide 
(CHX) addition. Graph show quantification of p53 levels at each time point. Data are means ± 
SEM (N = 3). 
(E) Immunoblot showing the abundance of p53 and MDM2 in Plk4AS cells at 16 hours after 
Nutlin-3 treatment.  
(F) Plk4AS; p53-/-, Plk4AS; 53BP1-/-, and Plk4AS; USP28-/- cells expressing SpCas9 were 
transduced with an sgRNA targeting SAS6. Monoclonal lines were isolated by limiting dilution. 
Each clone was transduced with a GFP-CEP63 expressing lentivirus and scored for the presence 
or absence of centrosomes. Individual clones were isolated and analyzed for SAS6 protein levels 
by immunoblot and fixed and stained with CEP192 antibodies to verify whether or not 
centrosome were present. As expected, cells lacking SAS6 always lacked centrosomes. Numbers 
represent the fraction of clones for each line that either did or did not contain centrosomes. All of 
the Plk4AS clones recovered contained SAS6 and centrosomes (49/49). However, SAS6 knockout 






Figure 19. The DNA damage response and centrosome surveillance pathway are genetically 
separable. 
(A) Immunoblot showing the level of various proteins at 1, 2 or 3 days after addition of DMSO 
or 3MB-PP1.  
(B) Fraction of cells with >5 53BP1 foci at times after addition of DMSO or 3MB-PP1. Data are 
means ± SEM (N = 3, >50 cells per experiment). 
(C) Immunoblot showing protein levels in Plk4AS; Chk2-/- cells. 
(D) Representative images of crystal violet stained colonies.  
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(E) Relative clonogenic survival of 3MB-PP1 or doxorubicin (10 ng/ml) treated Plk4AS cells. 
Data are means ± SEM (N = 3). 
(F) Immunoblot showing protein levels in Plk4AS; RNF168-/- cells. 
(G) Images show the loss of 53BP1 foci formation in doxorubicin-treated Plk4AS; RNF168-/- 
cells. Scale bar = 5 µm.  
(H) Graph shows the relative clonogenic survival of Plk4AS and Plk4AS; RNF168-/- cells treated 
with 3MB-PP1. Data are means ± SEM (N = 3). 
(I) Graph showing the relative clonogenic survival of doxorubicin-treated (10 ng/ml) Plk4AS 




Figure 20. Knockout of 53BP1 or USP28 does not allow growth in cells overexpressing 
Plk4.  
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(A) Graph shows the relative clonogenic survival of 3MB-PP1 treated Plk4AS cells grown in the 
presence or absence of the ATM inhibitor KU-55933. Data are means ± SEM (N = 2, performed 
in duplicate). 
(B) Immunoblot showing the level of phosphorylation of the ATM substrate, KAP1 S824, in 
cells treated with doxorubicin in the presence or absence of KU-55933. 
(C) Plk4AS cells were treated with doxorubicin (10 ng/ml) for 24 hours and then labeled with 
EdU for a further 12 hours. Graph shows the fraction of EdU-positive cells. Data are means ± 
SEM (N = 2, >150 cells per experiment).  
(D) Graph shows the relative clonogenic survival of Myc-Plk4WT overexpressing cells. Data are 
means ± SEM (N = 2, performed in duplicate). 
(E) Immunoblot showing protein levels in Plk4AS; LATS1-/- and Plk4AS; LATS2-/- cells. Graph 
shows the relative clonogenic survival of 3MB-PP1 treated Plk4AS; LATS1-/- and Plk4AS; 
LATS2-/- cells. Data represents two independent knockout clones for LATS1 and LATS2. 
(F) Immunoblot showing protein levels in Myc-Plk4WT cells expressing individual sgRNAs 
targeting LATS1 and LATS2. Graph shows the relative clonogenic growth of induced Myc-
Plk4WT cells. Data are means ± SEM (N = 2). 
(G) Images showing the localization of p53, 53BP1 and USP28 in interphase and mitosis. Scale 





Figure 21. Prolonged prometaphase and centrosome loss signal through the same 
components to arrest the cell cycle.  
(A) Mitotic duration in Histone H2B-EGFP expressing p53-/-, 53BP1-/- and USP28-/- Plk4AS cells, 
grown in either DMSO or 3MB-PP1 for six days. Data are means ± SEM (N = 2, >25 cells per 
experiment). 
(B) Schematic of the mitotic timer experiment. Graph shows the prometaphase duration and 
proliferative capacity of 3MB-PP1-treated Plk4AS cells. Each bar represents a daughter cell; its 
height represents the prometaphase duration of the mother cell, and its color represents the fate 
of the daughter. The dashed red line indicates the maximum time that mother cells spend in 
prometaphase before > 85% of daughter cells undergo a cell cycle arrest.  
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(C) Mitotic duration in Histone H2B-EGFP expressing Plk4AS cells. Measurements were taken 
over a 24 hr period at indicated times after 3MB-PP1 addition. Data are means ± SEM (N = 2, 
>25 cells per experiment). 





Centrosome loss is synthetic lethal with high 
TRIM37 expression in 17q23-amplified 
breast cancer cells 
 
4.1   Introduction 
Breast cancer is the most commonly diagnosed cancer in the US, with 268,670 new cases 
expected in 2018. Breast cancer is comprised of several distinct subtypes that lead to differences 
in response to various treatment modalities and clinical outcomes. Before the rise of high-
throughput technologies, the prognosis of breast cancers relied heavily on physical 
characteristics, such as tumor size and histological grade, as well as expression patterns of 
estrogen, progesterone, and HER2 receptors (Tang et al., 2008). We are now in the emerging age 
of genomics, where tumors can be more precisely characterized by defining the specific genetic 
alterations that drive disease progression (Kittaneh et al., 2013; Massard et al., 2017). These 
methods have aided efforts to better understand the relationship between cancer genotype and 
therapeutic responsiveness. One notable success story in this field is the identification of an 
Achilles’ heel in tumors containing BRCA1/2 null mutations. Treatment of BRCA1/2 null 
tumors with PARP inhibitors results in a potent synthetic lethal effect. However, as only 5-10% 
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of breast tumors are caused by inherited mutations in BRCA1/2, there is a need to identify 
additional molecular vulnerabilities that can be exploited therapeutically. 
 
The recognition of this need has driven major efforts to define breast cancer subgroups and their 
molecular drivers. One such sweeping study analyzed >2000 breast cancer samples, integrating 
multiple levels of genomic and transcriptomic information such as copy number and gene 
expression to classify them into 10 subgroups (Curtis et al., 2012). One subgroup of interest is 
defined by an amplification of the 17q23 chromosomal locus, which was associated with high 
levels of genome instability and poor prognosis. The prevalence of this amplification has been 
reported to range from 18-20% (Kallioniemi et al., 1994; Monni et al., 2001). The amplicon can 
be up to 4 MB in size, and may contain up to 50 genes. Expression profiling of the amplicon 
identified several genes that were consistently overexpressed in tumors containing the amplicon, 
of which RPS6KB1, TBX2, and PPM1D genes appear to be likely oncogenic drivers (Monni et 
al., 2001; Sinclair et al., 2003). The TRIM37 gene is also highly expressed from this region, and 
encodes a 108 kDa E3 ubiquitin ligase. Recent studies have implicated TRIM37 in controlling 
the microtubule nucleating capacity of cells, though its relevant targets remain unclear 
(Meitinger et al., 2016a). 
 
Centrosomes are the major microtubule-organizing centers of the cell, and help to catalyze the 
formation of the bipolar mitotic spindle. While centrosomes increase the efficiency of spindle 
assembly, centrosome-independent pathways exist to facilitate spindle formation (Heald et al., 
1997; Khodjakov et al., 2000; Prosser and Pelletier, 2017). Microtubule nucleation can also 
occur through chromosome- and microtubule-mediated pathways, which are able to spawn 
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sufficient microtubules for spindle assembly when centrosomes are absent. These three pathways 
for microtubule nucleation are at least partially redundant, though deficiencies in any one 
pathway results in mitotic delays which could result in genome instability. 
 
While non-transformed cells are able to undergo successful mitoses in the absence of 
centrosomes, dividing under these conditions triggers a cell cycle arrest (Lambrus et al., 2015; 
Wong et al., 2015b). This is due to the activation of a mitotic surveillance pathway that signals 
through a 53BP1-USP28-p53-p21 axis, which triggers a G1 arrest following prolonged mitoses 
(Fong et al., 2016a; Lambrus et al., 2016; Meitinger et al., 2016a). Cells that do not have an 
intact mitotic surveillance pathway, however, are able to proliferate robustly in the absence of 
centrosomes. As the majority of cancers have disrupted p53 or p21 pathways and grow well in 
the absence of centrosomes, centrosome depletion is not a generally effective therapeutic 
strategy against cancers (Wong et al., 2015b). In this chapter, we describe our surprising 
discovery of a novel synthetic lethal relationship in which centrosome loss induced with PLK4 
inhibition promotes cell death in breast cancers with high levels of the TRIM37 oncoprotein. 
 
4.2   MCF-7 breast cancer cells are hypersensitive to centrinone, independent 
of the mitotic surveillance pathway 
While evaluating the response of various cell lines to centrosome loss, we discovered that MCF-
7 breast cancer cells exhibited a striking growth arrest when treated with the PLK4 inhibitor 
centrinone (Fig. 22A-B). To test whether this growth arrest was dependent on the mitotic 
surveillance pathway, we generated knockouts for the core components of this pathway 
(TP53BP1, USP28, and TP53) in MCF-7 cells (Fig. 23A-B). In contrast to RPE-1 cells, which 
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readily proliferate in centrinone when the mitotic surveillance pathway is disrupted (Fong et al., 
2016b; Lambrus et al., 2016; Meitinger et al., 2016b), the growth of MCF-7 cells was not 
enhanced by loss of mitotic surveillance components (Fig. 22A-B, Fig. 23A).  
 
4.3   The sensitivity of MCF-7 cells to centrinone is dependent on 
overexpression of the TRIM37 oncoprotein 
The hypersensitivity of MCF-7 cells to PLK4 inhibition stands in contrast to the majority of 
tumor cancer cell lines, which proliferate robustly in the absence of centrosomes (Moyer et al., 
2015; Wong et al., 2015c). This led us to consider whether MCF-7s may be sensitized to 
centrosome loss by their genetic background. MCF-7s notably possess an amplification of 
chromosomal locus 17q23, an amplicon found in ~20% of breast cancers (Kallioniemi et al., 
1994; Kuukasjarvi et al., 1997). In MCF-7s, this region spans 4 MB and contains ~40 protein-
encoding genes (Monni et al., 2001; Parssinen et al., 2007; Sinclair et al., 2003). Among these is 
TRIM37, a gene encoding a 108 kDa E3 ubiquitin ligase previously implicated in centrosome 
function (Balestra et al., 2013; Meitinger et al., 2016b), although its centrosomal substrates are 
not known. Knockdown of TRIM37 leads to PCM accumulation, enabling more robust and rapid 
spindle assembly in cells that lack centrosomes (Fong et al., 2016b; Meitinger et al., 2016b). We 
therefore reasoned that conversely, high levels of TRIM37 may reduce PCM levels and suppress 
spindle assembly efficiency, thereby increasing sensitivity to centrosome loss. To test this 
synthetic lethal relationship, we generated an MCF-7 cell line stably expressing a TRIM37 
shRNA, which reduced TRIM37 levels by 90% (Fig. 22C). TRIM37 knockdown in MCF-7 cells 
resulted in a nearly four-fold improvement (increased from 25% to 88% in p53-/- background) in 
growth in centrinone compared to cells expressing a scrambled shRNA (Fig. 22E-F). This effect 
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was further supported by a marked rescue of cell viability by TRIM37 knockdown in centrinone-
treated MCF-7 cells (Fig. 22E). We conclude that elevated expression of TRIM37 renders MCF-
7 cells hypersensitive to centrinone treatment.  
 
4.4   TRIM37 overexpression is synthetic lethal with PLK4 inhibition in 
HCT116 and RPE-1 cells 
To test whether increased expression of TRIM37 is sufficient to cause synthetic lethality with 
PLK4 inhibition, we generated HCT116 p53-/- cells with constitutive overexpression of TRIM37 
or eGFP. While either centrinone treatment or TRIM37 overexpression alone only slightly 
impaired the growth of HCT116 p53-/- cells, combined treatment resulted in dramatic growth 
inhibition (Fig. 22G, Fig. 23C-D). This demonstrates that TRIM37 overexpression is sufficient 
to drive synthetic lethality in cells that normally tolerate centrosome loss. 
 
To confirm the lethal effect of centrinone in cells with high levels of TRIM37 was due to 
inhibition of PLK4 and not an off-target effect on another kinase, we generated doxycycline-
inducible p53-/- RPE-1 cells carrying an endogenously expressed analogue-sensitive (AS) allele 
of PLK4 (PLK4AS) (Lambrus et al., 2016). While inhibition of PLK4AS with the bulky ATP 
analogue 3MB-PP1, or overexpression of TRIM37, had a minor impact on cell proliferation, 
inhibition of PLK4 in combination with TRIM37 overexpression led to a dramatic suppression of 
cell growth (12 colonies, vs. 115 in 3MB alone and 97 with TRIM37 overexpression alone) (Fig. 




4.5   PLK4 inhibition is synthetic lethal in 17q23 amplified breast cancer cells 
To test whether the synthetic lethal effect is present in other breast cancer lines containing the 
17q23 amplicon, we assayed BT474 and MDA-MB-361 cells, which express TRIM37 at levels 
similar to that observed in MCF-7 cells (Fig. 24A). In accord with the response observed in 
MCF-7 cells, BT474 and MDA-MB-361 cells exhibited a strong growth defect in centrinone that 
was rescued by TRIM37 knockdown (Fig. 22I-J, Fig. 24B). Furthermore, an analysis of relative 
growth of these three 17q23-amplified breast cancer lines shows severe growth inhibition in 
centrinone, compared to the same treatment in p53-deficient RPE-1s and DLD-1 and U2OS cells 
that do not carry the 17q23 amplicon (Fig. 24C). Together, these results show that tumor cells 
carrying the 17q23 amplicon express high levels of TRIM37 and consequently exhibit a strong 
sensitivity to centrosome loss induced by PLK4 inhibition.  
 
4.6   MCF-7s undergo prolonged and aberrant mitosis upon centrinone 
treatment 
To determine how PLK4 inhibition leads to a growth arrest in MCF-7 cells, we monitored MCF-
7 p53-/- cells expressing H2B-iRFP and EGFP-tubulin by timelapse microscopy. We chose to use 
the p53-/- background to study mitotic defects without influence from the mitotic surveillance 
pathway. MCF-7 cells were first treated with centrinone or DMSO for 3 days, then filmed for 24 
hours (Fig. 25A). While DMSO-treated MCF-7 cells progressed through mitosis normally, 
47.4% of the centrinone-treated cells failed to form a bipolar spindle and either remained 
arrested in mitosis for the duration of the movie or slipped out of mitosis without undergoing 
anaphase (Fig. 25B-C). Importantly, knockdown of TRIM37 restored bipolar spindle formation 
in centrinone-treated MCF-7 cells, resulting in a dramatic decrease in mitotic duration (from an 
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average of 6.2 to 2.2 hrs) and cell division errors (from 47.4% to 9.9%) (Fig. 25C-E). These data 
suggest that high levels of TRIM37 antagonize spindle assembly in MCF-7 cells lacking 
centrosomes. 
 
4.7   Identifying TRIM37 proximity partners using proximity-dependent 
biotinylation 
To understand the mechanism by which high TRIM37 levels drive synthetic lethality with 
centrosome loss, we sought to identify TRIM37 interactors using proximity-dependent biotin 
labeling, a method which exploits a mutated, promiscuous form of Escherichia coli biotin ligase 
(BirA*) to biotinylate proteins within a ~10 nm radius (Roux et al., 2012). We generated a 
doxycycline-inducible lentiviral construct containing TRIM37 tagged with mTurbo, an 
optimized version of BirA* with enhanced efficiency (Branon et al., 2018). Biotin-labeling 
experiments were performed in RPE-1 cells, where mTurbo-TRIM37 was expressed ~2-4-fold 
above endogenous levels (Fig. 26A). To identify TRIM37 proximity partners, expression of 
mTurbo-TRIM37 or mTurbo alone was induced for 24 hrs before biotin was supplied for 
labeling for 6 hrs. To compare between mitotic and interphase interacting partners, we enriched 
for mitotic cells by adding dimethylenastron (an Eg5 inhibitor) 2 hrs after biotin addition. 
Mitotic and interphase biotinylated samples were harvested separately, captured with 
streptavidin-coated beads and bound proteins identified by mass spectrometry.  
 
We thresholded for hits with > 2-fold higher peptide representation in mTurbo-TRIM37 samples 
compared to mTurbo alone. This identified 184 TRIM37 proximity interaction partners, 7 of 
which have been previously reported as TRIM37 interactors (Fig. 27A). The top 30 hits with the 
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most spectral counts are listed in Fig. 26B. Gene ontology analyses showed a statistical 
enrichment of centrosomal proteins within this data set (Fig. 26C), which was corroborated by a 
clear enrichment of biotinylated proteins at the centrosome in biotin-labeled cells expressing 
mTurbo-TRIM37 (Fig. 26D). One of the most enriched hits is CEP192, a well-established 
component of the pericentriolar material (PCM) of centrosomes. This is consistent with a 
previous study which showed that depletion of TRIM37 allows the accumulation of PCM foci 
containing CEP192 (Meitinger et al., 2016b).  
 
4.8   Overexpression of TRIM37 reduces PCM levels and suppresses 
microtubule nucleation in MCF-7 cells 
To directly test if TRIM37 regulates the abundance of PCM proteins, we first examined cell-
wide levels of the PCM components CEP192, CEP152, Pericentrin, and CDK5RAP2 in cells 
with reduced or elevated TRIM37 expression. Knockdown of TRIM37 resulted in a modest 
increase in the levels of most PCM components in MCF-7 cells, while acute overexpression of 
TRIM37 in RPE-1 cells dramatically suppressed the levels of the same proteins (Fig. 27A). To 
determine the impact of elevated TRIM37 levels in mitosis, we measured the abundance of PCM 
at mitotic centrosomes in MCF-7 cells. Depletion of TRIM37 led to an increase in centrosomal 
CEP192, Pericentrin, and CDK5RAP2 to a level comparable to that observed in RPE-1 cells 
(Fig. 27B-C). To determine whether this increase in PCM abundance has an effect on 
microtubule nucleation, we performed microtubule regrowth assays on control and TRIM37-
depleted MCF-7 cells. We found that, consistent with the observed increase in PCM levels, 
mitotic centrosomes in TRIM37-depleted cells nucleated nearly twice the amount of alpha-
tubulin compared to control cells (Fig. 28A-B). The levels of EB1, a plus-end tracking marker of 
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growing microtubules, were also increased more than 3-fold on centrosomes in TRIM37-
depleted cells. We conclude that TRIM37-dependent suppression of PCM levels in MCF-7 cells 
leads to reduced microtubule nucleation from the centrosome. 
 
4.9   Non-centrosomal PCM aids in mitotic spindle assembly when 
centrosomes are depleted 
We next sought to analyze whether PCM suppression results in decreased microtubule nucleation 
in the absence of centrosomes, which we hypothesize to underlie the synthetic lethality of high 
TRIM37 levels with centrinone treatment. MCF-7 control and TRIM37-knockdown cells were 
treated with centrinone for 5 days to remove centrosomes, then examined by 
immunofluorescence for the presence of acentrosomal PCM aggregates that aid in spindle 
assembly. We found that in cells lacking centrosomes, 30-40% of TRIM37-depleted MCF-7s 
exhibited non-centrosomal PCM aggregates interacting with spindle microtubules, while this was 
almost never observed in control MCF-7 cells (Fig. 27D-E). These observations are consistent 
with a model in which high TRIM37 expression suppresses cellular PCM levels that are required 
to coordinate mitotic spindle assembly in the absence of centrosomes. 
 
To further test the proposal that reduced microtubule nucleation by the PCM is synthetic lethal 
with centrosome loss, we depleted the core PCM protein CEP192 with two independent shRNAs 
in RPE-1 p53-/- PLK4AS cells. CEP192 levels were reduced to a similar level to that observed in 
wild type MCF-7 cells (Fig. 29A-C, Fig. 27C).  As predicted, depletion of CEP192 increased the 
sensitivity of RPE-1 p53-/- cells to centrosome loss (58% growth in centrinone-treated control 
RPE-1 cells, compared to 24% and 28% in two-independent CEP192-shRNA clones) (Fig. 27F). 
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Furthermore, timelapse analysis showed that RPE-1 shCEP192 cells lacking centrosomes 
exhibited delayed mitotic centrosome maturation and an inability to form a bipolar spindle (Fig. 
27G-H). These phenotypes that were strikingly similar to those observed in MCF-7 cells 
depleted of centrosomes (Fig. 25). We conclude that reducing cellular PCM levels increases 
sensitivity to centrosome loss. 
 
4.10   TRIM37 levels are cell cycle regulated 
Given that centrosomal PCM expands dramatically prior to mitotic entry (Woodruff et al., 2014), 
we considered the possibility that TRIM37 abundance may be regulated in a cell cycle dependent 
manner to allow mitotic PCM accumulation. We used synchronized RPE-1 cells to assess 
TRIM37 levels at different stages of the cell cycle and found that TRIM37 levels peak in early S 
phase and reduce significantly by late-S/G2 (Fig. 30A-E). TRIM37 levels continue to decline 
and reach the lowest levels in mitosis, which corresponds with the time of PCM expansion. To 
test if low-levels of TRIM37 are required for the sharp increase in centrosome-driven 
microtubule nucleation in late G2, we examined the effect of TRIM37 expression levels on the 
timing of centrosome-mediated microtubule nucleation in late G2 phase.  Overexpression of 
TRIM37 in RPE-1 cells delayed the time of centrosome activation from 30 ±5 mins to 13 ±5 min 
prior to nuclear envelope breakdown (NEBD). Moreover, the timing of centrosome activation in 
MCF-7 cells occurred 20 ±10 mins earlier in cells depleted of TRIM37 compared with control 
cells (Fig. 31A-D). These data suggest that high levels of TRIM37 at G2/M phase delay the 
onset of microtubule nucleation by the centrosome. 
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4.11   TRIM37 overexpression drives genomic instability 
We noticed that overexpression of TRIM37 in RPE-1 cells led to striking increase in the DNA 
damage marker γH2A.X and stabilization of p53 and p21 (Fig. 32A). Consequently, TRIM37 
overexpression caused a cell cycle arrest that was overcome by p53 loss. This suggests that 
rather than being a passive passenger in the 17q23 amplicon, increased TRIM37 copy number 
may confer oncogenic properties that contribute to genome instability and tumor evolution. 
Supporting this hypothesis, cytogenetic analyses of RPE-1 cells show that acute overexpression 
TRIM37 increases the incidence of abnormally separated sister chromatids from ~15% to ~60% 
(Fig. 32B). To assess whether mitotic errors caused by TRIM37 overexpression could be 
propagated and promote genome instability, we analyzed the short-term effect of TRIM37 
overexpression on chromosome segregation errors in p53-/- RPE-1 cells using time-lapse 
microcopy. Although all of the p53-/- RPE-1 control cells analyzed (n=91) underwent successful 
divisions, we observed a dramatic increase in the incidence of mitotic slippage in cells 
overexpressing TRIM37 (Fig. 32C). 70% of the cells that failed mitosis progressed through the 
cell cycle and divided a second time (Fig. 32C), suggesting that TRIM37 overexpression drives 
whole-genome duplication events that can be propagated in subsequent divisions. 
 
To more directly test whether elevated levels of TRIM37 contribute to the genetic instability 
observed in MCF-7 cells, we examined the effect of TRIM37 knockdown on the fidelity of cell 
division in p53-/- MCF-7 cells. Knockdown of TRIM37 reduced the rate of mitotic errors from 
7.5% (n=84 cells) down to 0% (n=110 cells) (Fig. 25C), indicating that reduced TRIM37 levels 
increase mitotic fidelity in MCF-7 cells. This suggests that high TRIM37 levels promote mitotic 
errors that result in whole-genome duplication, a phenomenon that often occurs early in tumor 
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evolution and serves as a precursor for subsequent subclonal diversification (Bielski et al., 2018; 
Ganem et al., 2007). 
 
4.13   Discussion 
While most cancer cell lines are able to proliferate robustly in the absence of centrosomes (Wong 
et al., 2015b) here, we show that breast cancer cells with amplification of the chromosomal 
region 17q23 are an exception. These cells undergo dramatic growth arrest following centrosome 
loss, an effect is dependent upon the high levels of TRIM37 in the 17q23 amplicon. How does 
TRIM37 overexpression result in vulnerability to centrosome loss? We propose a model in 
which high levels of TRIM37 suppress CEP192 below a critical threshold, preventing its ability 
to facilitate microtubule nucleation and bipolar spindle assembly in the absence of centrosomes 
(Fig. 32D). This model is consistent with the identification of CEP192 as a strong proximity-
interactor with TRIM37, and the recapitulation of the synthetic lethal phenotype by CEP192-
shRNA functional assays. Normally, cells depleted of centrosomes depend on non-centrosomal 
pathways to assemble a bipolar mitotic spindle. These include contributions of microtubule (MT) 
nucleation from existing MTs and the chromatin-generated RanGTP gradient (Prosser and 
Pelletier, 2017). Importantly, all three MT nucleation pathways share a requirement for γ-tubulin 
ring complexes (γTuRCs) to serve as MT nucleation sites (Luders et al., 2006), and γTuRCs 
themselves rely on a CEP192 scaffold for their activation (Gomez-Ferreria et al., 2007; Joukov et 
al., 2014; Kollman et al., 2011; Yang and Feldman, 2015). Our results suggest that in MCF-7s, 
high TRIM37 levels suppress CEP192 and thereby suppress the activation of γTuRCs, 
preventing the nucleation of non-centrosomal MTs. Supporting this hypothesis, siRNA-mediated 
CEP192 depletion was reported to result in “disorganized spindles” and delayed centrosome 
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maturation (Gomez-Ferreria et al., 2007), which are identical phenotypes to those seen following 
TRIM37 overexpression. Taken together, these results suggest that CEP192 is a major TRIM37 
target underlying the synthetic lethal effect with centrosome loss in 17q23-amplified cancer 
cells. However, TRIM37 has many other putative interacting partners that may contribute to this 
phenotype, so a true test of this model depends on phenotypic rescue by CEP192 overexpression. 
 
Cancers harboring the 17q23 amplicon are associated with higher genome instability and poor 
prognosis (Curtis et al., 2012; Hermsen et al., 1998; Isola et al., 1995). The results presented here 
show a synthetic lethal effect between centrosome loss and cancers containing the 17q23 
amplicon, which suggest a new mechanism-based approach for treatment of this subset of 
tumors. The use of Plk4 inhibitors in clinical trials is already underway (Bedard et al., 2016), and 
have been well-tolerated and show favorable pharmacokinetic profiles, supporting the possibility 
of centrosome depletion as a therapeutic strategy. Future work exploring the responsiveness of 
cancer cell line and patient-derived xenografts to Plk4 inhibition will be an important next step in 
testing this therapeutic strategy. 
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4.14   Figures and Legends 
 
Figure 22. PLK4 inhibition is synthetic lethal with TRIM37 amplification in 17q23-
amplified breast cancer cells. 
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(A) Long-term clonogenic survival assay of MCF-7 and RPE1 cells with indicated genotypes 
treated with DMSO (control) or Plk4 inhibitor centrinone (125 nM). After 14 days, colonies were 
fixed and stained with crystal violet.  
(B) Graph showing the fold increase in cell number after centrinone addition. Centriole loss 
leads to an irreversible cell-cycle arrest. Points show the mean of three independent experiments. 
(C) Western blot analysis of TRIM37 protein levels in p53+/+ and p53-/- MCF-7 cells transduced 
with TRIM37-targeting shRNAs or vector control. Tubulin served as loading control. 
Representative data; n  = 3 independent experiments. 
(D) MCF-7 cells characterised in (C) were treated with DMSO (control) or Plk4 inhibitor 
centrinone for 10 days, fixed, and stained with crystal violet. 
(E) Representative images of fields of centrinone or DMSO-treated MCF-7 cells in (D). 
(F) Quantification of data in (D). Data normalized to DMSO control for each group. n = 3 
independent experiments. Mean  ±  s.d.  
(G) Long-term clonogenic survival assay of centrinone-treated HCT116 cells of indicated 
genotypes transduced with lentivirus expressing eGFP (control) or TRIM37 protein. n  = 3 
independent experiments. 
(H) Long-term colony survival assay of p53-/- Plk4AS hTERT-RPE1 cells expressing GST 
(control) or TRIM37 under a doxycycline-inducible system treated with DMSO (control) or ATP 
analogue 3MB-PP1. n = 3 independent experiments. Mean  ±  s.d. AS, analogue sensitive. 
(I) 17q23-amplified cell lines BT474 and MDA-MB-361 transduced with TRIM37-targeting 
shRNAs or vector control were similarly treated as in (D). 




Figure 23. TRIM37 overexpression in HCT116s and RPE-1s recapitulates synthetic 
lethality with centrosome loss. 
(A) Long-term clonogenic survival assay of MCF-7 and RPE1 cells with indicated genotypes 
treated with DMSO (control) or PLK4 inhibitor centrinone.  
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(B) Western blot characterization of HCT116 p53+/+ and p53-/- cells transduced with lentiviral 
constructs to allow for constitutive eGFP or TRIM37 overexpression. β-Actin was used as a 
loading control. 
(C) Quantification of data in Fig. 1g. Data normalized to DMSO control for each group. n = 3 
independent experiments. Mean  ±  s.d.  
(E) Long-term colony survival assay of p53-/- Plk4AS hTERT-RPE1 cells expressing GST 
(control) or TRIM37 under a doxycycline-inducible system treated with DMSO (control) or ATP 
analogue 3MB-PP1. AS, analogue sensitive.  
(F) Representative images of fields of p53-/- Plk4AS hTERT-RPE1 cells treated as in (E). 
 
 
Figure 24. Additional characterization of TRIM37 expression and synthetic lethality in 
17q23 cell lines. 
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(A) WB of a panel of 17q23 amplified (MDA-MB 361, BT474, MCF-7) and non-amplified 
(RPE1) cell lines expressing control (CNTL) or TRIM37 shRNA. β-Actin was used as a loading 
control. 
(B) Growth assay counted at day 8, performed over three independent replicates. 
(C) Representative images of fields of DMSO or PLK4i treated MDA-MB 361 and BT474 cells 




Figure 25. PLK4 inhibition triggers mitotic catastrophe in TRIM37 amplified cancer. 
(A) Experimental schematic. 
(B) Representative timelapse images of mitotic progression in DMSO- and centrinone-treated 
MCF-7s labeled with H2B-iRFP and EGFP-tubulin. 
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(C) Quantification mitotic duration and mitotic phenotype in ctrl MCF-7s compared to those 
expressing TRIM37-shRNA. Data acquired over of two independent timelapses, number of cells 
labeled above bars. 
(D) Example of the efficiency of TRIM37 knockdown in MCF-7s expressing constitutive 
TRIM37-shRNA. 
(E) Representative timelapse images of mitotic progression in DMSO- and centrinone-treated 




Figure 26. mTurbo identifies putative proximity interactors of TRIM37 
(A) Western blot for TRIM37 and biotinylated proximity interactors. Ponceau stain was used to 
gauge relative loading. 
(B) Thresholded mass spectrometry results, displaying the top 30 proximity interactors by 
spectral count and filtered for those with >2x more peptides in the mTurbo-TRIM37 sample 
compared to control. 
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(C) Gene ontology analysis of mass spectrometry data. 




Figure 27. Depleted PCM upon TRIM37-amplification is responsible for mitotic 
catastrophe in the absence of centrosomes. 
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(A) Immunoblot showing levels of TRIM37 and PCM components in MCF-7 and RPE-1 
following TRIM37 knockdown or overexpression, respectively. Normalized levels, averaged 
over three independent replicates, are shown in table format. 
(B) Representative images of centrosomal PCM levels in control and TRIM37-shRNA 
expressing MCF-7 mitotic cells. 
(C) Quantification of centrosomal PCM signal in mitotic cells, comparing MCF-7 control, MCF-
7 TRIM37-shRNA, and RPE-1 control samples. 
(D) Example images of centrinone-treated MCF-7s, illustrating the different observed 
distributions of PCM foci in centrinone-treated cells. 
(E) Quantification of PCM foci distribution in mitotic, centrinone-treated MCF-7s that lacked 
centrosomes (n = 3, >25 cells per experiment). 
(F) Relative growth after an 8 d growth assay with control and CEP192-shRNA expressing RPE-
1 Plk4AS p53-/- cells, showing a ratio of growth in PLK4i over DMSO. 
(G) Mitotic duration in RPE-1; p53-/-; Plk4AS cells expressing H2B-EGFP and TagRFP-tubulin, 
either control or expressing CEP192-shRNA, grown in either DMSO or 3MB-PP1 for 3 d. Data 
are means ± SEM (n = 2, >30 cells per experiment). 
(H) Quantification of frequency of mitotic errors in of the same samples as described in (G). 





Figure 28. TRIM37 suppresses microtubule organizing capacity of the centrosome. 
(A) Representative images of microtubule regrowth following nocodazole washout in control 
and TRIM37-shRNA expressing MCF-7 mitotic cells. 
(B) Quantification of microtubule regrowth following nocodazole washout in control and 




Figure 29. CEP192 is depleted following stable shRNA expression. 
(A) Immunoblot showing the CEP192 levels in RPE-1; p53-/-; Plk4AS cells, comparing parental 
control cells with those expressing CEP192-shRNA. 
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(B) Quantification of mitotic centrosomal CEP192 signal in the same cells as described in (A). 





Figure 30. TRIM37 protein levels are downregulated during mitosis. 
(A) Schematic of the experimental protocol used for cell cycle synchronization. M, mitotic phase  
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(B) Representative flow cytometry plots of synchronized cell cycle samples harvested according 
to a. Samples were subjected to dual flow cytometry staining of pH3 (mitotic cells) and 
propidium iodide (PI) to determine synchronization efficiency. Top, RPE-1; Bottom, MCF-7. N 
= 3 independent experiments. AS, asynchronous. 
(C) DNA content analysis of samples from b by flow cytometry. Left, RPE-1; Right, MCF-7.  
(D) Mitotic Index of cell cycle samples was determined by quantification of the percentage of 
pH3-positive cells with 4N DNA content from the analysis in (B). Mean  ±  s.d.  
(E) Western blot analysis of endogenous TRIM37, cyclin A and phospho-histone H3 in samples 






Figure 31. TRIM37 overexpression results in delayed centrosome maturation during 
mitotic entry. 
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(A) Quantification of centrosomal alpha-tubulin intensity from timelapse movies of dividing 
cells, in RPE-1 tet-on TRIM37 cells in minus- or plus-dox conditions. (n = 1, >20 cells). 
(B) Quantification of centrosomal alpha-tubulin intensity from timelapse movies of dividing 
cells, in MCF-7 cells expressing either control or TRIM37 shRNA. (n = 1, >20 cells). 
(C) Representative timelapse images of centrosome maturation in MCF-7 cells. 




Figure 32. TRIM37 overexpression promotes genome instability. 
(A) Western blot analysis of RPE1 p53+/+ cells overexpressing TRIM37 under a doxycycline-
inducible system. Samples were taken at 8, 24, 48 and 72 hours (h) post doxycycline addition. 5 
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Gy irradiation (IR) and 4 µM Nutlin-3 (N3) treatment were used as positive controls for the 
induction of DNA damage and p53 responses respectively. β-Actin was used as a loading 
control. 
(B) Bottom; Representative metaphase images of sister chromatid pairing phenotypes (normal, 
abnormal and partial) observed in spreads of RPE1 p53-/- cells overexpressing GST (control) or 
TRIM37 for 48 h. Top; Quantification of the phenotypes observed in each condition. n = 3 
independent experiments, between 106 and 137 metaphases were analysed in each experiment. 
Mean  ±  s.d. 
(C) An analysis of mitotic duration and cell fate over the course of a 60-hour timelapse. (n = 2, 
>90 cells total). 











hTERT-RPE-1 cells were grown in DMEM:F12 medium (Corning Cellgro) containing 10% fetal 
bovine serum (Sigma), 0.348% sodium bicarbonate, 100 U/ml penicillin, 100 U/ml streptomycin 
and 2 mM L-glutamine. HEK293FT cells were grown in DMEM medium (Corning Cellgro) 
containing 10% fetal bovine serum (Sigma), 100 U/ml penicillin, 100 U/ml streptomycin and 2 
mM L-glutamine. Cells were maintained at 37°C in a 5% CO2 atmosphere with 21% oxygen. 
Nocodazole (Sigma) was dissolved in DMSO and used at a final concentration of 3.3 µM, 
Mimosine (Sigma) was dissolved in dilute HCl and used at a final concentration of 250 µM, 
PD0332991 (PD, Sigma) was dissolved in DMSO and used at a final concentration of 1 µM, 
SB203580 (Sigma) was dissolved in DMSO and used at a final concentration of 10 µM, 
doxorubicin (Sigma) was dissolved in water and used at a final concentration of 200 ng/mL, and 
indole-3-acetic acid (IAA, Sigma) was dissolved in water and used at 500 µM unless otherwise 
stated. 3MB-PP1 (Millipore) was dissolved in DMSO and used at a final concentration of 10 
µM, centrinone (a kind gift from Karen Oegema, Ludwig Institute for Cancer Research, CA) was 
dissolved in DMSO and used at a final concentration of 125 nM, cycloheximide (Sigma) was 
 106 
dissolved in water and used at a final concentration of 50 µg/ml, KU-55933 (TOCRIS) was 
dissolved in DMSO and used at a final concentration of 10 µM, and Nutlin-3 (Cayman 
Chemical) was dissolved in DMSO and used at a final concentration of 10 µM unless otherwise 
stated. 
 
Creation of Plk4AID/AID  hTERT-RPE-1 cells 
Gene targeting was performed using Adeno-Associated Virus (AAV) (Berdougo et al., 2009; 
Holland et al., 2012b). To generate the Plk4 targeting construct we cloned an AID degron 
followed by a 3xFLAG epitope tag, a translational stop codon, the Plk4 3′ UTR and 150 bp’s of 
adjacent genomic sequence into the pBluescript derivative pNY to create the AID-3xFLAG-
3′UTR, loxP-NeoR-loxP vector. 5′ and 3′ homology arms were PCR amplified from genomic 
RPE1 DNA and cloned on either side of the central AID-3xFLAG-3′UTR, loxP-NeoR-loxP 
cassette. The entire insert was transferred into the pAAV vector backbone and fully sequenced to 
verify its integrity.  hTERT-RPE1 cells were transduced with infectious AID-3xFLAG-
3′UTR;loxP-NeoR-loxP-containing AAV particles. Plk4AID/+ cells were isolated by selection in 
G418 and resistant clones screened by PCR using primers binding in NeoR and a genomic 
sequence adjacent to the targeting construct. A second targeting construct was created containing 
a HA tag in place of the FLAG epitope tag and a BlastR in place of NeoR. An additional round of 
gene targeting was performed in Plk4AID/+ cells using AID-HA-3’UTR;loxP-BlastR-loxP AAV 
particles. The intergenic position of the NeoR and BlastR cassettes reduces the likelihood that 
their presence will disrupt the function of the Plk4 gene. This facilitates the isolation of 
homozygous targeted alleles by allowing concurrent selection for both markers. Plk4AID/AID cells 
were isolated by co-selection in G418 and Blasticidin and resistant clones screened by PCR 
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using primers that bind in BlastR and a genomic sequence adjacent to the targeting construct. 
Two independent Plk4AID/AID clones were created and the targeted Plk4-AID-3xFLAG and Plk4-
AID-3xHA alleles were sequenced to verify their integrity. osTIR1-9xMyc was cloned into the 
pBabe backbone under the control of the gag promoter and introduced into Plk4AID/AID cells using 
retroviral delivery. Stable integrants were selected in 5 µg/ml puromycin and single clones 
isolated by limiting dilution. EGFP-tagged Cep63 was cloned into the FUGW backbone under 
the control of the Ubiquitin promoter, while EGFP-tagged histone H2B and TagRFP-Tubulin 
were cloned into the FUGW backbone under the control of the CMV promoter. All three 
constructs were introduced into Plk4AID/AID cells using lentiviral delivery and single clones 
isolated by limiting dilution. A p53 shRNA was introduced into cells using lentiviral delivery 
and single clones isolated using fluorescence activated cell sorting (Tiscornia et al., 2003). 
 
Creation of Plk4AS hTERT-RPE-1 cells 
To facilitate genome editing, we set out to knockout out the puromycin acetyltransferase (PAC) 
expressed in hTERT-RPE-1 cells. An sgRNA targeting PAC (TGTCGAGCCCGACGCGCGTG) 
was cloned into the px458 expression vector (Addgene #48138) that coexpresses the sgRNA 
from a U6 promoter and SpCas9-2A-GFP from a CMV promoter. Cells were transfected with the 
px458 plasmid and GFP-positive single cells isolated by FACS. Clones were split into duplicate 
wells and one well received 3 µg/ml puromycin. A clone that showed complete cell death after 3 




Plk4 gene targeting was performed in hTERT-RPE-1 cells using CRISPR/Cas9. In brief, a 
sgRNA targeting Plk4 (AGATAGCAATTATGTGTATC) was cloned into the px459 expression 
vector (Addgene #48139) that coexpresses the sgRNA from a U6 promoter and SpCas9-2A-
puromycin from a CMV promoter. Cells were cotransfected with a 1:20 molar ratio of the px459 
plasmid and a 160-bp single-stranded oligonucleotide repair template. The repair template 
introduced the L89G mutation, a silent AflIII restriction site, and a mutation in the SpCas9 
protospacer adjacent motif (PAM) to prevent recutting after homology-directed repair. 
Transfected cells were selected for 3 days with 3 µg/ml puromycin and single clones were 
isolated by limiting dilution. Genomic DNA was isolated from single clones and subjected to 
PCR using the following primers (forward, GCAGGAATGGTACAGAGAGTCC; reverse, 
GCAAAACTTTTATCCACCCAAA). PCR products were digested with AflIII for 2 h. Clones 
with digested PCR products were sequenced to verify insertion of the L89G mutation. A single 
clone was identified that possessed the L89G mutation in one allele and a frameshift single 
basepair insertion in the second allele that led to the creation of a premature stop codon at amino 
acid 94.  






A C-terminal Plk4 fragment (amino acid 510-970) was cloned into a pET-23b bacterial 
expression vector (Novagen) containing a C-terminal 6xHis tag. Recombinant protein was 
 109 
purified from E. coli using Ni–NTA beads (QIAGEN) and used for immunization (ProSci). A 
STIL C-terminal peptide VGTFLDVKRLRQLPKLF (amino acid 1271-1287) was synthesized 
and conjugated to KLH for immunization. Rabbit immune sera were affinity purified using 
standard procedures. Affinity purified antibodies were directly conjugated to DyLight 550 and 
DyLight 650 fluorophores (Thermo Scientific) for use in immunofluorescence. 
 
Immunoprecipitation of FLAG-Plk4 
To purify Plk4-AID-3xFLAG, cells were lysed in lysis buffer (10 mM Tris pH 7.5, 0.1% Triton 
X-100, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 20 mM, β-glycerophosphate, 
0.1 mM DTT, 200 nM microcystin, 1 mM PMSF and 1 mM LPC), sonicated and soluble extracts 
prepared. The supernatant was incubated with anti-FLAG M2 magnetic beads (Sigma). Beads 
were washed 5 times in lysis buffer and immunopurified protein analyzed by immunoblot.  
 
Western Blotting 
For immunoblot analysis protein samples were separated by SDS-PAGE, transferred onto 
nitrocellulose membranes with a Trans-Blot Turbo Transfer System (BioRad) and then probed 
with the following antibodies: DM1A (mouse anti-α-tubulin, Sigma, 1:5000), Plk4 (rabbit, this 
study, 1:3200), FLAG M2 (mouse, Sigma, 1:1000), STIL (rabbit, Bethyl, 1:2500), Yap (rabbit, 
Cell Signaling, 1:1000), p-Yap Ser127 (rabbit, Cell Signaling, 1:1000), LATS2 (rabbit, Cell 
Signaling, 1:1000), p-LATS S1077 (rabbit, (Yu et al., 2010), a kind gift of Duojia Pan, Johns 
Hopkins School of Medicine, 1:500), p-Histone H2A.X (Ser139) (rabbit, Cell Signaling, 
1:1000), YL1/2 (rat anti-α-tubulin, Pierce Antibodies, 1:3000), p53 (mouse, CalBiochem, 
1:1000), 53BP1 (rabbit, Novus Biologicals, 1:2000), MDM2 (mouse, Thermo Fisher Scientific, 
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1:1000), Chk2 (mouse, EMD Millipore, 1:500), phospho-KAP1 (Ser824) (rabbit, Bethyl, 
1:1000), phospho-p53 (Ser15) (rabbit, Cell Signaling, 1:1000), CDKN1A (rabbit, NeoBioLab, 
1:1000), RNF168 (rabbit, Millipore, 1:1000), and LATS1 (rabbit, Cell Signaling, 1:1000). 
 
Immunofluorescence 
For immunofluorescence, cells were grown on 18-mm glass coverslips and fixed for 10 min in 
either 4% formaldehyde at room temperature, or 100% ice cold methanol at -20°C for 10 
minutes. Cells were blocked in 2.5% FBS, 200 mM glycine, and 0.1% Triton X-100 in PBS for 1 
hour. Antibody incubations were conducted in the blocking solution for 1 hour. DNA was 
detected using DAPI and cells were mounted in Prolong Antifade (Invitrogen). Staining was 
performed with the following primary antibodies: GTU-88 (mouse anti-γ-tubulin, Abcam, 
1:250), Centrin (mouse, Millipore, 1:1000), CNAP1 (guinea pig, raised against the CNAP1 
peptide sequence SPTQQDGRGQKNSDAKC, a kind gift from Olaf Stemmann, University of 
Bayreuth, Germany, 1:1000), CEP152 (rabbit, Bethyl, 1:5000), Plk4-650 (directly labeled rabbit, 
this study, 1:1000), STIL-550 (directly labeled rabbit, this study, 1:1000), CEP135 (rabbit, raised 
against CEP135 a.a. 695-838, a kind gift from Anthony Hyman, Max Planck Institute for 
Molecular Cell Biology and Genetics, Germany, 1:1000), CEP192-Cy3 (directly-labeled rabbit, 
raised against CEP192 a.a. 1-211, a kind gift from Karen Oegema, Ludwig Institute for Cancer 
Research, CA, 1:1000), SAS6-Cy3 (directly-labeled rabbit, raised against SAS6 a.a. 501-657, a 
kind gift from Karen Oegema, Ludwig Institute for Cancer Research, CA, 1:1000), SAS6 
(mouse, Santa Cruz Biotechnology, 1:1000), CPAP-Cy3 (directly-labeled rabbit, a kind gift from 
Karen Oegema, Ludwig Institute for Cancer Research, CA, 1:1000), CENP-F (sheep, raised 
against CENP-F a.a. 1363-1640, a kind gift from Stephen Taylor, the University of Manchester, 
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UK, 1:1000), HA (rat anti-HA High Affinity, Roche, 1:200), FLAG (mouse anti-FLAG M2, 
Sigma, 1:1000), p53 (mouse, CalBiochem, 1:1000), 53BP1 (rabbit, Novus Biologicals, 1:2000), 
53BP1 (mouse, Millipore, 1:1000), USP28 (rabbit, Proteintech, 1:1000), p-Histone H2A.X 
(Ser139) (rabbit, Cell Signaling, 1:1000), CEP192-Cy5 (directly-labeled goat, raised against 
CEP192 a.a. 1-211, this study, 1:1000), and BUB1 (sheep, raised against BUB1 a.a. 336-489, a 
kind gift from Stephen Taylor, the University of Manchester, UK, 1:1000). Secondary donkey 
antibodies were conjugated to Alexa Fluor® 488, 555 or 650 (Life Technologies). 
 
For the cell cycle analysis of Plk4 levels shown in Figure 1E, cells were pulsed with EdU for 1 
hour prior to fixation in 100% ice cold methanol at -20°C for 10 minutes. Cells were washed 
three times with 0.1% Triton X-100, stained using a Click-It EdU Alexa Fluor 555 imaging kit 
(Life Technologies) and blocked in 2.5% FBS, 200 mM glycine, 0.1% Triton X-100 in PBS for 1 
hour. Immunofluorescence microscopy was performed using the following antibodies: CENP-F 
(sheep, raised against CENP-F a.a. 1363-1640, a kind gift from Stephen Taylor, the University of 
Manchester, UK, 1:1000), GTU-88 (mouse anti-γ-tubulin, Abcam, 1:250), and Plk4-650 (directly 
labeled rabbit, this study, 1:1000). G1 phase cells were classified as CENP-F and EdU negative, 
S phase cells were classified as EdU positive, and G2 phase cells were classified as CENP-F 
positive and EdU negative. The γ-tubulin staining was used to define the position of the 
centrosome. 
 
For EdU analysis of cell cycling, cells were pulsed with EdU for 12 hours prior to fixation in 
100% ice cold methanol at -20°C for 10 minutes. Cells were washed three times with PBST and 
stained using a Click-It EdU Alexa Fluor 555 imaging kit (Life Technologies). 
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Immunofluorescence microscopy and image analysis 
Immunofluorescence images were collected using a Deltavision Elite system (GE Healthcare) 
controlling a Scientific CMOS camera (pco.edge 5.5). Acquisition parameters were controlled by 
SoftWoRx suite (GE Healthcare). Images were collected at room temperature (25°C) using an 
Olympus 40x 1.35 NA, 60x 1.42 NA or Olympus 100x 1.4 NA oil objective at 0.2 µm z-sections 
and subsequently deconvolved in SoftWoRx suite. Images were acquired using Applied 
Precision immersion oil (N=1.516).  For quantitation of signal intensity at the centrosome, 
deconvolved 2D maximum intensity projections were saved as 16-bit TIFF images. Signal 
intensity was determined using ImageJ, by drawing a circular region of interest (ROI) around the 
centriole (ROI S). A larger concentric circle (ROI L) was drawn around ROI S. ROI S and L 
were transferred to the channel of interest and the signal in ROI S was calculated using the 
following formula:  
IS - [(IL-IS/AL-AS) x AS] 
A = Area, I = Integrated pixel intensity. 
For quantitation of nuclear p53 signal intensity, 2D maximum intensity projections were saved as 
16-bit TIFF images, and DAPI signal was used to threshold nuclei as regions of interest. For 
each nucleus, the integrated density of p53 signal was divided by nuclear area to give a 
signal/area value. Data were averaged over all cells in the panel, and normalized to untreated 
population. 
 
Live cell microscopy 
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Cells were seeded into 4-chamber, 35 mm glass bottom culture dishes (Greiner) and maintained 
at 37°C in an environmental control station. Images were collected using a Deltavision Elite 
system (GE Healthcare) controlling a Scientific CMOS camera (pco.edge 5.5.). Images were 
acquired with a Olympus 40x 1.35 NA oil lens using Applied Precision immersion oil 
(N=1.526). Every 5 minutes, 7 x 3 µm z-sections were acquired for EGFP and RFP and 
maximum intensity projection created using softWoRx (Applied Precision). Alternatively, cells 
were imaged using a Zeiss 40x 1.4 NA PlanApochromat oil-immersion objective on a Zeiss 
LSM 780 confocal equipped with a solid-state 488 nm and 514 nm laser and a spectral GaAsP 
detector. Images were acquired using Carl Zeiss immersion oil (N=1.518). Acquisition 
parameters, shutters, and focus were controlled by ZEN black software (Zeiss). 15 X 1.6 µm z-
sections were acquired simultaneously for EGFP and/or RFP at 5 or 10 min time intervals. 
Maximum intensity projections were created using ZEN black. Movies were assembled and 
analyzed using FIJI. Mitotic duration was calculated as the time taken from nuclear envelope 
breakdown to mitotic exit. 
 
Mitotic timer experiments and cell lineage tracing 
For nocodazole treatment, coverslips were assembled into observation chambers with medium 
containing 0.08 µM nocodazole and fields of cells were continuously followed by video time-
lapse microscopy at 37°C for 6 hours. After 6 hours, the field of view was marked with a 
diamond scribe; the bottom of the observation chamber was removed and washed out with fresh 
medium several times before being reassembled with fresh medium as previously described 
(Uetake and Sluder, 2012). The previously marked fields were continuously followed for at least 
96 hours. Lineage tracing of individual cells was performed as previously described (Uetake et 
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al., 2007). For IAA and SB203580 treatment, cells were exposed to the drug for the duration of 
imaging. Images were collected using a Leica DMRXE microscope equipped with phase-contrast 
optics and a Leica 10x 0.3 NA objective. Images were captured with an Orca ER (Hamamatsu) 




Cells were grown on 35 mm Nunclon Delta-treated culture dishes (Thermo Scientific) and fixed 
(2.5% glutaraldehyde, 3 mM MgCl2, 0.1 M sodium cacodylate, pH 7.2) for one hour at room 
temperature. Cells were rinsed with 0.1 M sodium cacodylate, and post-fixed with 0.5% 
OsO4 for one hour on ice. Following a dH2O rinse, plates were stained with 0.1% tannic acid, 
rinsed twice with dH2O, and stained en bloc with 2% aqueous uranyl acetate. Samples were 
dehydrated in a graded series of ethanol, embedded in Eponate 12 resin (Ted Pella), and 
polymerized at 60°C overnight. Ultrathin 60 nm sections were cut, mounted, and stained with 
1% tannic acid, followed by 2% uranyl acetate and lead citrate. Images were acquired using a 




To prepare cells for flow cytometry, cell pellets were fixed in cold 70% EtOH for 24 hours, 
washed once in PBS and resuspended in PBS supplemented with 0.5 mg/ml RNAse A and 50 
mg/ml Propidium Iodide (PI). Samples were incubated at room temperature for 30 minutes and 
analyzed on a flow cytometer (FACSCalibur; Becton Dickinson). For RNA interference, 2 x 105 
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cells were seeded in a 6-well plate and duplexed siRNAs introduced using RNAiMax (Life 
Technologies). siRNA directed against STIL (5’ GCUCCAAACAGUUUCUGCUGGAAU-3’) 
was purchased from Dharmacon.  
 
Cell clonogenic and growth assays 
For clonogenic assays, 500 cells were seeded in a 10 cm2 culture dish and left to grow for ∼10 
days until colonies were visible by eye. Cells were fixed in methanol for 30 min at room 
temperature and colonies were stained with crystal violet (Sigma-Aldrich). Plates were imaged 
on a G:BOX Chemi XX6 (Syngene) and the fraction of the dish upon which growth occurred 
was determined using GeneSys software (Syngene). The percentage clonogenic survival was 
calculated by dividing the area of growth in the presence of 3MB-PP1 by the area of growth of 
control DMSO-treated cells multiplied by 100.  
 
Lentiviral production and transduction 
The lentiCas9-Blasticidin (Addgene #52962), lentiGuide-Puromycin (Addgene #52963) or 
lentiGuide-Neomycin (this study) plasmid was co-transfected into 293FT cells with the lentiviral 
packaging plasmids psPAX2 and pMD2.G (Addgene 12260 and 12259). Briefly, 8 x 106 293FT 
cells were seeded into a Poly-L-Lysine coated 15 cm culture dish the day before transfection. For 
each 15 cm dish the following DNA was diluted in 1.2 ml of OptiMEM (Thermo Fisher 
Scientific): 9 µg of lentiviral vector, 12 µg of psPAX2 and 3 µg of pMD2.G. Separately, 72 µl of 
1 µg/µl 25 kDa polyethylenimine (PEI; Sigma) was diluted into 1.2 ml of OptiMEM, briefly 
vortexed, and incubated at room temperature for 5 min. After incubation, the DNA and PEI 
mixtures were combined, briefly vortexed, and incubated at room temperature for 20 min. 
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During this incubation, the culture media was replaced with 17 ml of pre-warmed DMEM + 1 % 
FBS. The transfection mixture was then added drop-wise to the 15 cm dish. Viral particles were 
harvested 48 hr after the media change and filtered through a 0.45 µm PVDF syringe filter. The 
filtered supernatant was either concentrated in 100 kDa Amicon Ultra Centrifugal Filter Units 
(Millipore) or used directly to infect cells. Aliquots were snap-frozen and stored at –80°C. For 
transduction, lentiviral particles were diluted in complete growth media supplemented with 10 
µg/ml polybrene (Sigma) and added to cells. 
 
CRISPR/Cas9 GeCKO screen 
CRISPR/Cas9 pooled, knockout screens were performed essentially as described (Chen et al., 
2015; Shalem et al., 2014). Briefly, PAC knockout hTERT-RPE1 or Plk4AS hTERT-RPE1 cells 
were transduced with the lentiCas9-Blasticidin virus and single cells sorted into 96-well plates to 
isolate clonal cell lines. Multiple clones were screened by immunoblot for the FLAG epitope 
fused to the Cas9 protein. A SpCas9-hTERT-RPE1 and Plk4AS-SpCas9-hTERT-RPE1 cell line 
with a high level of SpCas9 expression was selected for further use.  
 
The human GeCKO v2 plasmid library was purchased from Addgene (#1000000049) and 
plasmid DNA amplified according to the manufacturers instructions. To produce virus, the 
GeCKO pooled plasmid library and the lentiviral packaging plasmids psPAX2 and pMD2.G 
were co-transfected into 40x 15 cm culture dishes of 293FT cells. Transfections were performed 




Cells were transduced with the GeCKO library via spinfection. To find the optimal virus 
volumes for achieving an MOI ~ 0.1, each new batch of virus was titered by spinfecting 3 x 106 
cells with several different volumes of virus. Briefly, 3 x 106 cells per well were  
seeded into a 12 well plate in growth media supplemented with 10 µg/ml polybrene. Each well 
received a different titrated virus amount (between 5 and 50 µl) along with a no-transduction 
control. The plate was centrifuged at 2,000 rpm for 2 hr at room temperature. After the spin, 
media was aspirated and fresh growth media was added. The following day, cells were counted 
and each well was split into duplicate wells. One well received 3 µg/ml puromycin (Sigma) for 3 
days. Cells were counted and the percent transduction calculated as the cell count from the 
replicate with puromycin divided by the cell count from the replicate without puromycin 
multiplied by 100. The virus volume yielding a MOI closest to 0.1 was chosen for large-scale 
transductions. An MOI of 0.1 - 0.2 corresponds to a single transduction percentage of 95% at 
10% survival and 90% at 20% survival, respectively.  
 
For the pooled screen a total of 12 x 107 SpCas9-hTERT-RPE1 or Plk4AS-SpCas9-hTERT-RPE1 
cells were infected at MOI ∼0.1 and selected with puromycin at 3 µg/ml for 3 days. MOI was 
calculated using a control well infected in parallel following the same procedure outlined above. 
Infected cells were expanded under puromycin selection for 7 days to allow editing to proceed to 
completion. After 7 days, 2 x 107 cells were spun down and frozen for genomic DNA extraction. 
In addition, 12 x 106 cells were seeded into each of two 15 cm culture dishes. One dish was 
treated with DMSO and the other with either centrinone (SpCas9-hTERT-RPE1 cells) or 3MB-
PP1 (Plk4AS-SpCas9-hTERT-RPE1 cells). Cells were either passaged or fresh media was added 
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every 3-4 days. Cell pellets with a minimum of 2 x 107 cells were taken at 42 days after drug 
addition at which point the screen was terminated. 
 
Frozen cell pellets were thawed and genomic DNA was extracted with a GenElute Mammalian 
Genomic DNA extraction kit (Sigma). The sgRNA library for each sample was amplified and 
prepared for Illumina sequencing using a two-step PCR procedure, where the first PCR includes 
enough genomic DNA to preserve full library complexity and the second PCR adds appropriate 
sequencing adapters to the products from the first PCR. For the first PCR, a region containing the 
sgRNA cassette was amplified using primers specific to the sgRNA-expression vector: 
lentiGuide-PCR-F: AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
lentiGuide-PCR1-R: CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCC  
 
The thermocycling parameters for the first PCR were: 98°C for 30 s, 18-24 cycles of (98°C for 1 
s, 62°C for 5 s, 72°C for 35 s), and 72°C for 1 min. 1.5 µg of DNA was used in each PCR 
reaction. Assuming 6.6 pg of DNA per cell, ~100x representation of the GeCKO library required 
~80 µg of DNA per sample (54 PCR reactions). The resulting amplicons for each sample were 
pooled, gel purified and used for amplification with barcoded second PCR primers. For each 
sample we performed 14 reactions.  
Primers for the second PCR include both a variable length sequence to increase library 
complexity and an 8 bp barcode for multiplexing of different biological samples:  
F2: 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC






5 µl of the product from the first PCR reaction were used and the thermocycling parameters for 
the second PCR were: 98°C for 30 s, 18-24 cycles of (98°C for 1 s, 70°C for 5 s, 72°C for 35 s). 
Second PCR products were pooled, gel purified and quantified using the Next Library 
Quantification Kit (NEB). Diluted libraries with 5% PhiX were sequenced with MiSeq 
(Illumina). 
 
Sequencing data were processed for sgRNA representation using custom scripts. Briefly, 
sequencing reads were first demultiplexed using the barcodes in the forward primer and then 
trimmed to leave only the 20 bp sgRNA sequences. The spacer sequences were then mapped to 
the spacers of the designed sgRNA library using Bowtie (Langmead et al., 2009). For mapping, a 
maximum of one mismatch was allowed in the 20 bp sgRNA sequence. Mapped sgRNA 
sequences were then quantified by counting the total number of reads. The total numbers of reads 
for all sgRNAs in each sample were normalized. Genes were ranked using the MaGeCK 
algortihm which takes into account sgRNA enrichment as well as the number of sgRNAs 
targeting a particular gene (Li et al., 2014). 
 
Statistics 
Differences were determined by one-tailed t test, and annotated following the nomenclature: ns 
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